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UNDERSTANDING NANOG’S ROLE IN CANCER BIOLOGY 
    Mark Daniel Badeaux, B.S. 
   Supervisory Professor Dean Tang, PhD 
 The cancer stem cell model holds that tumor heterogeneity and population-level 
immortality are driven by a subset of cells within the tumor, termed cancer stem cells.  
Like embryonic or somatic stem cells, cancer stem cells are believed to possess self-
renewal capacity and the ability to give rise to a multitude of varieties of daughter cell.  
Because of cancer’s implied connections to authentic stem cells, we screened a variety 
of prostate cancer cell lines and primary tumors in order to determine if any notable 
‘stemness’ genes were expressed in malignant growths.  We found a promising lead in 
Nanog, a central figure in maintaining embryonic stem cell pluripotency, and through a 
variety of experiments in which we diminished Nanog expression, found that it may play 
a significant role in prostate cancer development.  We then created a transgenic mouse 
model in which we targeted Nanog expression to keratin 14-expressing in order to assess 
its potential contribution to tumorigenesis.  We found a variety of developmental 
abnormalities and altered differentiation patterns in our model , but much to our chagrin 
we observed neither spontaneous tumor formation nor premalignant changes in these 
mice, but instead surprisingly found that high levels of Nanog expression inhibited 
tumor formation in a two-stage skin carcinogenesis model.  We also noted a depletion of 
skin stem cell populations, which underlies the wound-healing defect our mice harbor as 
well.  Gene expression analysis shows a reduction in c-Jun and Bmp5, two genes whose 
loss inhibits skin tumor development and reduces stem cell counts respectively. 
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 As we further explored Nanog’s activity in prostate cancer, it became apparent 
that the protein oftentimes was not expressed.  Emboldened by the competing 
endogenous RNA (ceRNA) hypothesis, we identified the Nanog 3’UTR as a regulator of 
the tumor suppressive microRNA 128a (miR-128a), which includes known oncogenes 
such as Bmi1 among its authentic targets.  Future work will necessarily involve 
discerning instances in which Nanog mRNA is the biologically relevant molecule, as 
well as identifying additional mRNA species which may serve solely as a molecular sink 
for miR-128a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
Table of Contents 
 
I.  K14.Nanog transgenic mouse model  
Chapter 1- Introduction and Background  1 
Adult stem cells and the cancer stem cell model   1 
Embryonic stem cells and cancer   4 
Nanog in ES cells    6 
Nanog in cancer    8 
Mouse skin and skin stem cells   10 
Two-stage skin carcinogenesis   14 
Anatomy of the prostate   17 
Proliferative diseases of the prostate   18 
Chapter 2- Materials and Methods   20 
Chapter 3- Characterization of K14.Nanog Mice   28 
Dose-dependent phenotypes in K14.Nanog mice   30 
Phenotypes-skin    31 
Wound healing defect in K14.Nanog mice   33 
Phenotypes-lens    38 
Phenotypes-lingual/digestive   39 
Phenotypes-thymus    40 
Chapter 4- Testing Nanog’s Effect on Tumor Development 44 
Lack of tumor development in transgenic mice   44 
Chapter 5- Skin Stem Cells and Gene Expression Analysis  50 
 viii 
Assessment of skin stem cell populations   50 
Chapter 6- Ongoing and Future Studies, Significance   58 
Prostate-specific Nanog expression:  A constitutive model   58 
Summary/Significance    59 
Future Studies    60 
 
II. Nanog and miR-128a 
Chapter 7-Introduction and Background   63 
MicroRNA- general information   63 
MicroRNAs and non-coding RNA species   66 
MicroRNA 128a- a candidate tumor suppressor   67 
Chapter 8- Materials and Methods   70 
Chapter 9- Examining the Nanog/miR-128a Axis    73 
Nanog regulation by miR-128a   70 
Mir-128a as a tumor suppressor in PCa   73 
Nanog mRNA miR-ly as a sponge?   75 
Chapter 10- Significance and Future Directions   78 
References     83 
Vita     98 
 
 
 
 
 ix 
                         List of Illustrations 
 
I.  K14.Nanog transgenic mouse model 
Figure 1-1 The Nanog protein   9 
Figure 1-2 Stem cell populations in the murine hair follicle  15 
Figure 3-1 Characterization of K14.Nanog transgenic mice   34 
Figure 3-2 Nanog protein expression in transgenic mice   35 
Figure 3-3 Characterization of Line 1 skin abnormalities   36 
Figure 3-4 K14 Nanog mice exhibit a wound-healing defect 37 
Figure 3-5 Shared lens phenotype between transgenic mice  41 
Figure 3-6 Digestive and Thymic Phenotypes at P5   42 
Figure 3-7 Abnormal differentiation K14. Nanog tongue  43 
Figure 4-1 Two-stage skin carcinogenesis    48 
Figure 4-2 Hyperplastic response to TPA treatment   49 
Figure 5-1 Diminution of hair follicle stem cell pools  51 
Figure 5-2 Epidermal gene expression panel    56 
Figure 5-3 c-Jun levels are reduced in K14.Nanog epidermis 57 
Figure 6-1 Characterization of ARR2Pb Nanog Mice  62 
 
II.  Nanog and miR-128a 
Figure 9-1 Mir-128a can regulate the Nanog 3’UTR   76 
Figure 9-2 Lowering Nanog levels increases miR-128a levels  77 
Figure 9-3 Mir-128a lessens PCa clonal and clonogenic growth 78 
 x 
 
List of Tables 
 
I.  K14.Nanog transgenic mouse model 
Table 3-1 Summary of BK5.Nanog injections   29 
Table 4-1 K14.Nanog/K5.Myc breedings     45 
Table 5-1 Primers used in epidermal gene expression studies 55 
 
 
  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
I.  K14. Nanog Transgenic Mouse Model 
Chapter 1-  Introduction and Background 
Introduction 
 Tumors are immortal, heterogeneous tapestries woven of various malignant cells, 
yet these disparate threads do not all have the same malignant potential.  The cancer 
stem cell model posits a hierarchy existing in tumor cells that is similar to hierarchies 
that may be found in many adult somatic tissues.  In an effort to understand at the 
molecular level some of the resemblance between cancer cells and stem cells, we have 
identified a number of stem cell genes that are expressed in prostate cancer and have 
focused on a particularly interesting master regulator of embryonic stem cells known as 
Nanog.  Extensive loss-of-function studies demonstrated that Nanog depletion greatly 
inhibited tumor development in xenograft models of prostate cancer.  In order to model a 
potential role for Nanog in tumorigenesis, we created transgenic mice in which tumor-
derived Nanog cDNA is driven by the keratin 14 promoter, thereby targeting its 
expression to a variety of stem cell populations.  
 
Background 
Adult stem cells and the cancer stem cell model  
 For many years it has been appreciated that tumors are possessed of multifarious 
cell types; what is less clear is the origin of these disparate sorts of cell.  Long-standing 
dogma has it that genetic instability in tumor cells produces competing cells within a 
tumor; cells that bear mutations that confer a selective advantage become dominant (1).  
This clonal evolution model is thought to operate dynamically and constantly in cancer, 
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such that sharp changes in the tumor’s environment (such as those that occur when 
chemotherapy is begun) are met with an ever-adapting population.  In sharp contrast to 
this model is the cancer stem cell (CSC) hypothesis, which postulates that cells bearing 
many of the same properties as adult stem cells generate the myriad cell types present in 
a given tumor (2); these properties may include self-renewal, relative dormancy, and an 
increased tolerance for genomic damage (as often occurs in chemotherapeutic regimens).  
In normally-functioning adult organs, tissues are highly organized and, for the 
most part, are arranged in a discernibly hierarchical manner with stem cells occupying 
the apex.  Oftentimes, the immediate progeny of adult stem cells is the transit-amplifying 
(TA) cell, also known as the progenitor cell.  These cells are characterized by high 
immediate proliferative activity, and the progenitor sits upstream of mature, terminally-
differentiated cells.  This latter cell type is the functional effector of its respective organ, 
and is characterized by a highly-specialized transcriptional program.  These cells have 
also irrevocably committed to their fate, and are generally believed to lose the ability to 
proliferate.  The notion that similar hierarchies exist in cancers is not a new one, but with 
the emergence and refinement of several techniques, especially fluorescence-activated 
cell sorting (FACS), amenable to isolating cell populations of interest, this notion has 
been much easier to test.  The CSC model gained significant traction in the mid-1990’s 
after two seminal studies by the Dick lab involving acute myelogenous leukemia (AML) 
in which they demonstrated that CD34+, CD38- cells alone could generate 
transplantable leukemia (3, 4).  CD34+/CD38- is, not coincidentally, the cell-surface 
phenotype borne by human hematopoietic stem cells.   
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 There has been much confusion in the scientific community due to the moniker 
“cancer stem cell”.  The term is functional and refers to the cell population that can 
regenerate tumors in a xenograft setting; to demonstrate self-renewal (of the tumor) with 
a reasonable degree of certainty, xenografts are done iteratively for several generations 
of tumor.  Additionally, these tumors must recapitulate the heterogeneity seen in the 
parental tumor to fully fit the definition of cancer stem cell.  This heterogeneity is thus 
assumed to arise from the ability of the CSC to give rise to its own spectrum of 
cancerous progeny.  CSCs need not necessarily originate from normal stem cells, 
although it is quite likely that, owing to the long-lived nature of adult stem cell 
populations, these more primitive cells are indeed prime targets for transformation.  
Progenitor cells, having replicative ability and some limited self-renewal abilities, may 
also suffer genetic and epigenetic alterations that yield CSCs.  It is unknown if 
terminally differentiated cells can undergo dedifferentiation or can be transformed into  
cancer stem cells, although such a scenario is considered unlikely. 
 Also unknown is whether solid tumors are arranged hierarchically, as many 
blood cancers seem to be.  One of the earliest reports identified cancer stem cells in 
breast cancers (5), although the fact that the samples utilized were not primary tumors, 
but rather pleural effusions and metastases, left open the question of whether or not 
primary breast tumors in fact were arranged in a hierarchy.  In the past ~7-8 years, there 
has been a deluge of reports claiming identification of CSC populations in nearly every 
sort of solid tumor.  Upon closer inspection, however, many of these reports are 
incomplete, oftentimes lacking the gold standard of serial in vivo xenotransplantation 
assays and/or demonstration of phenotypic heterogeneity in tumor regrowths.   
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 The question of whether prostate cancers behave according to the cancer stem 
cell model is the subject of many labs’ research, including our own.  This question has 
been impossible to definitively address, as technical limitations render xenograft 
regrowth of primary prostate tumors null.  This is even true when employing different 
sites of injection and/or adding Matrigel or other reagents to augment cell engraftment.  
Instead, xenograft prostate tumors or tumors derived from pre-established cancer cell 
lines, e.g., PC3, DU145, and LNCaP have been used as surrogates in these experiments.  
In this context, it has been shown that CD44+ cells are significantly enriched in CSC 
activity (6).   
 
Embryonic stem cells and cancer 
 Superficially, one may see a resemblance between an embryo and a cancerous 
growth, in that both have a high rate of proliferation, near-limitless proliferative 
potential, and exist in an undifferentiated state.  However, the embryo is carrying out a 
highly orchestrated program that results in a functional organism, whereas the neoplasia 
grows wantonly.  There remains nonetheless a connection between the two, for the 
embryo and its in vitro derivative, the embryonic stem cell (ES cell), possess two traits 
important for sustained activity:  They are multipotent, that is, they can give rise to 
numerous cellular lineages, and they possess the quality of self-renewal, or the ability to 
replenish themselves at the population level.  Both of these qualities are evident in 
cancers as well, leading one to wonder if perhaps they share any common molecular 
features as well.  In the past four years, a number of groups have conducted large-scale 
gene expression forays in which similarities between ES cells and various cancers, 
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including lung and bladder malignancies, have been noted (7-9).  An underlying 
assumption of such similarities is a global similarity in epigenetic landscape that is then 
manifested in the form of gene expression mimicry.    It has been reported that 
intractable hypermethylation of the promoter regions of Polycomb group target genes 
occurs both in ES cells and in many cancer cells as well (10); enticingly, many of these 
genes are established or candidate tumor suppressors.  Additionally, it has been 
speculated that the presence of a bivalent chromatin state in ES and adult stem cells, one 
composed of methylation at the tail of histone 3 at lysine 27 and at lysine 4, and one that 
is believed to be poised for activation of neighboring genes, may predispose cancer cells 
to repression of these genes through a scant few additional repressive events (11). 
 Reports of shared gene expression such as those enumerated above raised the 
question as to whether or not ES cells share common transcriptional machinery with 
somatic cancer cells.  Nanog, Oct4, and Sox 2 represent the core triad of transcription 
factors that serve to maintain the pluripotent (able to give rise to all cell lineages save 
placental) state, acting as hubs in a large-scale protein network dedicated to pluripotency 
(12, 13).  Quite often, these transcription factors work together, occupying each other’s 
promoters and binding many common promoter regions as well (14).  In fact, binding of 
multiple (more than four) transcription factors is oftentimes required for gene expression 
from a particular locus in ES cells, and those genes with low transcription factor 
occupancy tend to be inactive (13).   
 Numerous studies have claimed re-expression of ES cell transcription factors in 
human cancers, although closer inspection reveals that the most substantive data is found 
at the level of mRNA expression, while confirmed reports of the ES cell transcription 
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factors themselves, such as Nanog’s role in glioma stem cells (15), are scarce.  There 
have been, however, a number of systems generated in order to test the potential 
contribution of these molecules to cancer development, e.g., Oct-4 and Nanog, when 
expressed together in a lung adenocarcinoma cell line (A549), result in increased in vitro 
sphere formation, an increase in the putative CSC population marked by CD133+, and 
larger tumors in a subcutaneous xenograft assay of tumor development (16).  The most 
compelling of these systems has been in the form of transgenic mouse models; because 
transcription factors are likely to exert highly cell-type-specific effects (see Klf4, whose 
overexpression in the breast is tumor inhibitory but leads to dysplasia in epidermal basal 
keratinocytes (17-19)), systems that target multiple organs are likely to yield the most 
comprehensive and useful insights.    A provocative study performed by the Jaenisch lab, 
which employed a doxycycline-inducible mouse model of Oct-4 overexpression from 
the Collagen1a1 locus, demonstrated epithelial dysplasia and epidermal tumor growth 
upon activation of Oct-4 (20).  The authors concluded, however, that despite its powerful 
potential contribution to tumor development, it was surprising that the molecule was 
rarely re-expressed in human tumors.  This fact suggested to them that the molecule was 
under epigenetic “lock and key,” perhaps because of its oncogenic potential. 
 
Nanog in ES cells 
As mentioned previously, Nanog is a homeobox transcription factor essential to 
maintaining pluripotency; it consists of 305 amino acids in both human and mouse 
homologues, and as such has a predicted molecular mass of 34 kilodaltons (Figure 1-1).  
The human and mouse Nanog proteins are ~60% similar at the amino acid level, but the 
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critical DNA-binding domains of the two proteins share over 90% homology.   The 
protein is organized into five functional domains:  The N-terminal domain seems to 
represent a docking site for other proteins (21), while the homeodomain is responsible 
for DNA-binding.  The C-terminal domains have transactivating ability (22-24), and 
between them lies the unique tryptophan repeat domain in which every fifth amino acid 
residue is a tryptophan.  This WR region is essential for Nanog dimerization, without 
which it cannot function to propagate the pluripotent state (25).  In ES cells, Nanog 
exists in a variety of protein complexes that range in size from 160kD to over 1 
megadalton (12).  Its gene was cloned as part of a cDNA library screen to identify 
factors responsible for scant yet reproducible mouse ES cell propagation in the absence 
of leukemia-inhibitory factor (LIF) (26, 27), which is necessary for mouse ES cell 
growth but dispensable for proliferation of human ES cells.  ES cells that have been 
engineered to lack Nanog can surprisingly self-renew, but in chimeric mice these cells 
cannot form functional germ cells.  Due to its role in establishing the inner cell mass 
(ICM) of embryos as well as in creating mature germ cells, it has been postulated that 
Nanog serves to resist differentiation signals, holding open a figurative window of 
pluripotency (28).   
The vast body of scientific study that has arisen in the wake of Yamanaka and 
colleagues’ discovery that adult somatic cells can be reprogrammed into ES-like cells 
called induced pluripotent cells (iPS cells) (29) has also led to insights concerning the 
factors that are crucial for this process.  Unsurprisingly, Nanog is a central figure in this 
reprogramming:  Without Nanog, partially de-differentiated/reprogrammed 
intermediates cannot attain full pluripotency.  ES cells that lack Nanog cannot invoke 
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reprogramming of somatic cells in the context of cell fusion, and Nanog has also been 
found to mark the developing epiblast.  In fact, in the absence of Nanog, the ICM forms 
but cannot attain full pluripotency; for this and the reasons enumerated above, it has 
been suggested that Nanog acts as the conduit to “ground state pluripotency” (30).   
 
Nanog in cancer 
Nanog expression has been reported in a variety of cancer types at the protein 
level, e.g., (31-33), although the veracity of many of these reports is questionable due to 
several concerns including reagent specificity.  More compelling evidence of Nanog 
gene expression exists in the form of mRNA-related data, e.g., (34-37). Our lab 
conducted pilot studies in a variety of prostate cancer cell lines, xenografts, and primary 
tumors in order to determine which potential stem cell factors were expressed in this 
spectrum of diseases, and found consistent expression of a Nanog retrogene, NanogP8, 
which encodes a protein identical to that encoded by the canonical Nanog gene (38).   
We then asked whether expression of Nanog may be important in tumor development.  
To answer this question, we conducted loss-of-function studies, utilizing Nanog small 
interfering RNA (siRNA) to show that diminishing Nanog levels reduces in vitro serial 
sphere-propagating ability, and utilizing lentiviral-mediated short hairpin RNA (shRNA) 
to show decreased tumorigenesis in subcutaneous xenografts of various cancer cell lines.  
For technical reasons, including unexplained cell death when overexpressing Nanog 
cDNA, we decided to conduct gain-of-function studies in a transgenic mouse model. 
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Figure 1-1 
 
 
 
Figure 1-1  The Nanog protein 
Nanog is a transcription factor comprised of 305 amino acids which has five known 
functional domains, as depicted in (A).  It is one of the central hubs in the protein-
protein interaction network devoted to maintaining pluripotency in the ICM(B), and 
associates cooperatively with other hub molecules such as Oct4, or repressively as 
exemplified by its binding to Smad1 which blocks Bmp signaling. 
Figure 1-1B is adapted from Wang et al. 2006  Nature 444:364-368. 
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We chose to utilize the keratin 5/keratin 14 promoters as they target basal cell 
populations in stratified squamous epithelia (39-42); these basal cells are known to 
harbor stem and/or progenitor cell populations.  These promoters have been shown to 
cause the most dramatic phenotypes in the skin, as promoter expression is strongest in 
this tissue.  Additionally, we chose to target the prostate, as most of our Nanog studies 
centered on prostate cancer, and therefore utilized the ARR2Pb promoter which has 
activity primarily in luminal cells of the prostate (43, 44). 
 
Mouse skin and skin stem cells 
The skin is a protective organ whose primary role is to serve as a barrier between 
an organism and its environment, and it is composed of three important regions:  The 
epidermis is home to epithelial cells that are nucleated, express keratins 5 and 14 (K5 
and K14), and are situated near the basement membrane but enucleate as they detach, 
begin to express keratins 1 and 10 (K1 and K10), and move suprabasally to form the 
highly keratinized, waxy outer layer of skin.  The dermis is populated chiefly by 
fibroblasts and is the region in which hair follicles and sebaceous glands are anchored.  
The hypodermis is primarily composed of fat and is an important mediator of 
temperature regulation, one of the skin’s ancillary duties. Contributing to this 
phenomenon in humans are sweat glands that secrete fluid when body temperature rises; 
evaporation of sweat removes heat from the body.  In colder climes, body hair serves to 
retain heat.  Mice lack the ability to sweat but retain body heat in part through the 
copious amount of fur that covers most of the animal, save the tail and feet.  
 11 
Anatomically, this distinction means that hair follicular density in mouse skin is much 
greater than that in human skin.   
 The differences in anatomical structure between adult human and mouse skin 
extend to the location of their respective stem cell populations.  In human skin, the basal 
layer of the epidermis has been shown to harbor cells capable of extensive clonal growth 
ex vivo.  Because of the relative paucity of hair follicles in the human skin, it is thought 
that the basal epidermal keratinocytes are the primary stem cell pool.  It should be noted 
that many of the techniques available to study mouse skin, such as lineage tracing and 
label-retention, are quite obviously not available to employ in human systems for ethical 
reasons, and therefore knowledge of human skin stem cells is scant when compared with 
the findings in mouse skin.   
 The murine interfollicular epidermis (IFE) is home to a population of basal cells 
with capacity for clonal expansion in vivo during steady-state conditions, and is thought 
to be the hub of the so-called epidermal proliferative unit (EPU) coined by Chris Potten 
(45).  There is some controversy as to whether these cells represent true stem cells or so-
called progenitor/transit-amplifying cells, but this may be a semantic argument, as 
functionally these “stem” cells are responsible for clonal repopulation of a localized area 
of the IFE. 
 Adult mouse skin’s resident stem cells are primarily localized in the hair follicle, 
and consist of several distinct populations, although it should be noted with some 
caution that the degree of overlap as well as the lineage relationships among these 
populations has not been fully explored, and given the rash of new stem cell populations 
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discovered in this tissue in the past two years, it is likely that there are as-yet-
undiscovered mouse skin stem cells.   
 The classical method for identifying mouse skin stem cells is the label-retaining 
experiment, first conducted using tritium-laden thymidine that is incorporated into DNA 
during S phase of the cell cycle (46), and now commonly performed using 5’-bromo 2’-
deoxyuridine (BrdU) in its stead.  Label-retaining cells (LRCs) are identified by first 
pulsing the mouse with the label to be used; the pulse is performed for a sufficient length 
of time such that all cells under study have been allowed to proliferate, and therefore 
have taken up the label.  The subsequent “chase” period is the empirically-determined 
window of time that the label is diluted through multiple rounds of cell division; only 
cells that have remained relatively quiescent during the chase will still bear the initial 
label at a detectable level.  This method for detecting quiescent skin cell populations 
revealed the presence of LRCs in the bulge region of the hair follicle as well as in the 
basal layer of the IFE. 
 Ex vivo, keratinocytes (usually from newborn mice, although adult keratinocytes 
can be used as well, albeit at much lower efficiencies) can be plated at clonal density on 
a low (~one-third confluent) density of 3T3 mouse fibroblast cells or on a variety of 
substrates (e.g. laminin, collagen IV) in defined media supplemented with growth factors 
and allowed to form colonies.  Tightly packed growths, known as holoclones, are 
believed to contain stem cells, whereas less-organized meroclones and paraclones may 
contain progenitors and differentiated cells, respectively (47). 
 The preferred current method of distinction among various cell populations is by 
way of cell-surface marker profile, since these populations can be prospectively isolated 
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by FACS and assayed for stem cell function by engrafting the population of interest, 
along with newborn dermal fibroblasts, onto the backs of immunocompromised mice 
and assessing the degree of contribution to new IFE, hair follicles, and sebaceous glands.    
 The chief resident hair follicle stem cell population is thought to be the alpha-6 
integrin+, CD34+ cells in the bulge region.  A subset of these cells additionally are 
LRCs, and this population is capable of reconstituting the epidermal lineages, including 
the IFE, the hair follicle, and the sebaceous gland, in their entirety. Current thought 
therefore places these cells at the top of the hair follicle stem cell hierarchy, as they 
demonstrate multipotency in vivo and in ex vivo artificial systems.   
 Bulge cells co-expressing CD34 and leucine-rich repeat-containing G-protein-
coupled receptor 5 (Lgr5) surprised researchers as they were found to be able to 
reconstitute all epidermal lineages in transplantation experiments but were also found to 
be actively cycling (48).   This finding challenged the paradigm of stem cells in the skin 
existing solely in a relatively quiescent state.  
 The observation that upon wounding, stem cells are surprisingly recruited from 
the infundibulum and isthmus rather than from the bulge and contribute significantly to 
the repair of affected areas, suggests that bulge keratinocytes are not the only reservoir 
of follicular stem cells.  Leucine-rich immunoglobulin-like 1 (Lrig1)-positive cells lie in 
the junctional zone between the infundibulum and the IFE.  As Lrig1 is a 
transmembrane, cell surface protein whose known role is to restrict epidermal growth 
factor receptor (EGFR) signaling by targeting it for ubiquitination and therefore 
degradation following EGFR stimulation (49, 50), it is thought to promote a relatively 
quiescent state. Although Lrig1+ cells  are capable, when mixed with neonatal dermal 
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fibroblasts and grafted onto immunocompromised hosts, of reconstituting all epidermal 
cell types,  lineage tracing experiments suggest that this population replenishes only the 
IFE and the sebaceous glands during normal homeostasis (51). 
Leucine-rich repeat-containing G-protein-coupled receptor 6 (Lgr6)-positive 
cells represent an interesting population, as they generate the three epidermal 
components prenatally, yet the adult population directly above the bulge only gives rise 
to IFE and sebaceous gland, but was found to be involved in wound repair (52).  There is 
some overlap between the Lrig1+ and Lgr6+ populations, but the extent of this shared 
pool has not been analyzed. 
 MTS 24-positive cells consist of two sorts:  Some lie directly above those cells 
that express CD34, and it has been noted that this population contains LRCs, although its 
ability to reconstitute hair follicles in a transplantation assay is unknown (53).  Another 
population cycles actively and has been shown to generate the three broad epidermal cell 
types . 
 
Two-stage skin carcinogenesis 
 A two-stage chemically-induced carcinogenesis protocol is among several 
experimental models available to researchers with an interest in studying tumor 
development in the skin.  It lists among its strengths the ability to delineate between the 
initiation and promotion phases of tumor development, and is easily superimposed upon 
pre-existing transgenic or knockout mouse lines as both the initiator and promoter may 
be delivered topically.   
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Figure 1-2 
 
 
 
Figure 1-2  Known stem cell populations in the murine hair follicle 
A number of cell-surface markers define stem cell populations in the hair follicle.  The 
degree of overlap and lineage relationship among the various populations is currently the 
subject of much research.  For further descriptions of each stem cell population please 
see the body of the text. 
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Genetic lesions are introduced into skin stem and progenitor cells (54) found in both the 
interfollicular epidermis and the hair follicle (55) by application of a single sub-
carcinogenic dose one of a diverse array of initiating compounds, among which 7,12-
dimethylbenz[a]anthracene (DMBA) is the most widely used.  Two members of the Ras 
G protein-coupled receptor family, Hras and Kras, sustain the relevant DMBA-induced 
mutational burden, resulting in largely dormant mutation-bearing cell populations that 
await proliferative stimuli in order to clonally expand.  It should be noted that the 
genetic insults induced by many initiators, including DMBA, are largely irreversible; 
accordingly, intervals between initiator and promoter treatment may span a range from 
two weeks to many months.   
After the initiator has been allowed sufficient time to be metabolized, the tumor 
promotion phase may begin.  Typically, 12-O-Tetradecanoylphorbol-13-acetate (TPA) 
or another phorbol ester compound is used to induce cellular proliferation.  TPA does so 
by activating Protein Kinase C (PKC), as TPA resembles diacylglycerol, one of PKC’s 
endogenous triggers.  PKC phosphorylates many proteins at serine and threonine 
residues; among the most important in the context of its activation in the two-stage 
carcinogenesis protocol is epidermal growth factor receptor (EFGR).  Indeed, signaling 
through PKC and in turn through EGFR has been shown to also activate Akt (protein 
kinase B) as a further downstream consequence (56).  Essentially, a host of 
phosphorylation events are initiated and signaling pathways activated when TPA is 
applied to the skin. The tumor promoter is generally applied topically two or more times 
per week, and it is essential that a regular schedule is adhered to, as the effects of 
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promoters are reversible, i.e., hyperplasia or papillomas induced by promotion will 
recede in the absence of treatment.  Promotion may last for 20 weeks to a full year, and 
during this time course epidermal hyperplasia will yield benign exophytic papillomas; 
cells in these small tumors may eventually sustain sufficient additional genetic insults 
such that the papilloma will progress to a squamous cell carcinoma (SCC).  SCCs 
resulting from the two-stage skin carcinogenesis protocol are in many respects similar to 
those that occur spontaneously in humans, and may be identified by their endophytic, 
vascularized nature.   
 There are several practical advantages to using a two-stage protocol rather than a 
one-stage, or complete, method.  In the latter, the distinction between initiation and 
promotion is obfuscated, while in the former both are readily separable (57).  In such a 
setting, a gene or compound of interest may be more accurately described with respect to 
its role in skin carcinogenesis.  Additionally, a gene’s contribution to the progression 
from premalignant lesion to frank cancer may also be assessed.  In any skin 
carcinogenesis protocol, mouse models that are recalcitrant to spontaneous tumor 
development may still be studied in the context of carcinogenesis.     
 It is also important to note the limitations of this experimental model.  First, it 
does not accurately recapitulate the genetic underpinnings of human skin cancer, as 
SCCs in this model are Ras-driven, while human skin cancers are largely reliant on p53 
inactivation (58).  Additionally, it cannot be used to address other cancer types due to the 
need for topical application of the relevant chemicals.  Finally, metastasis of the SCCs 
produced is rare, relegating the protocol chiefly to the study of benign growths and 
primary tumors.    
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Anatomy of the prostate  
The prostate is a small, hormone-responsive, exocrine organ tasked with 
producing and secreting fluids that aid in sexual reproduction.  The mouse prostate is 
grossly unlike that of humans, in that the latter is a small uniform walnut-sized organ 
while the latter contains four lobes (anterior, dorsal, lateral, and ventral) arranged around 
the urethra.  Histologically, however, the two are organized similarly:  The tubules that 
comprise the gland possess epithelial cells that overlie supporting stroma.  The prostatic 
epithelium consists of basal cells that are anchored to the basement membrane and that 
express K5 and K14, differentiated secretory luminal cells that express keratins 8 and 18 
(K8 and K18), and neuroendocrine cells that are interspersed throughout the basal layer. 
The most commonly used construct for targeting a gene of interest to the prostate 
is the androgen-responsive probasin promoter, or more properly, the artificial derivative 
known as the ARR2Pb promoter, which has two androgen response regions (ARRs) 
immediately upstream of the minimal probasin promoter (44).  Genes cloned into 
constructs bearing this promoter are expressed primarily in the luminal cells of the 
mouse prostate, although scant expression in basal and even stromal compartments can 
be observed (unpublished observations).  Expression is likewise stronger in some lobes 
than others, with dorsal and ventral expression being much higher than expression in the 
anterior prostate ((44) and unpublished observations).  The promoter is extremely 
sensitive to androgen levels, and as such achieves maximum activity as the mouse 
reaches sexual maturity at roughly eight weeks of age (44).   
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Proliferative diseases of the prostate 
Two of the most common diseases of the prostate are benign prostatic 
hyperplasia and prostate cancer.  The latter is of particular importance since it may 
metastasize and cause significant mortality in untreated or treatment-refractory male 
populations.  Prostate cancer in humans occurs in a multi-step fashion, from normal 
gland to prostatic intraepithelial neoplasia (PIN) lesion to prostatic adenocarcinoma.  
The cell of origin for prostate cancer is a point of contention among various groups, but 
decades of pathological evidence suggests that luminal expansion is the primary 
manifestation of the disease.   
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Chapter 2- Materials and Methods 
Mouse Housing and Care 
All housing and procedures were carried out in an animal facility accredited by 
the American Association for the Assessment and Accreditation of Laboratory Animal 
Care, in accordance with Institutional Animal Care and Use Committee guidelines.  
Mice were fed ad libitum unless otherwise noted.  
  
Generation of K14-NanogP8 Mice 
The basic procedures for establishing transgenic (Tg) animals have been 
previously described.  Briefly, the NanogP8 open-reading frame cDNA derived from 
HPCa5T, a primary human prostate tumor, was cloned into the multiple cloning site 
(MCS) of the pBluescript-human keratin 14 vector, in which the human keratin 14 
promoter is immediately followed by a rabbit b-globin intron and the MCS is followed 
by an SV40 poly-A tail (see Fig. 1-1A for a schematic). The K14 promoter directs 
expression to several tissue types, including basal cells of the skin, prostate, bladder, 
forestomach, tongue, mammary myoepithelium, kidney papilla, and pancreatic ductal 
epithelia.  
 
Screening for K14-Nanog Mice 
Mouse tail snips or ear punches were collected and lysed in a solution containing 
25 mM NaOH and 0.2 mM EDTA at 95°C for 30 minutes, after which neutralization 
buffer (40 mM Tris-HCl, pH 5) was added (HOTSHOT PROTOCOL). Five mL of this 
sample was added to 20 mL polymerase chain reaction (PCR) reaction mixture 
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consisting of 12.5 mL 2x GoTaq Mastermix (Promega), 5.5 mL ddH2O, and 1 mL each 
of b-globin forward primer (5’-GGG-CAA-CGT-GCT-GGT-TAT-3’) and NanogP8 
reverse primer (5’-CCT-TTG-GGA-CTG-GTG-GAA-3’) at 10 mM. PCR was carried 
out for 35 cycles consisting of a standard melting step, an annealing temperature of 58°C 
and a 45-second extension at 72°C.  Products were run on a 1.5% agarose gel containing 
ethidium bromide and were visualized using UV light.  Transgenic mice were identified 
as those bearing a ~300-bp product.  Alpha Imager software (Alpha Innotech) was used 
to collect images. 
 
Epidermal Lysate  
Mouse dorsal skin was shaved and Nair was applied to remove remaining hair 
stubble.  The hair-free skin was scraped on ice using a straight-blade razor and epidermis 
was scraped until shiny dermis was evident.  The epidermal scrapings were added to 
lysis buffer containing 25 ul/mL protease inhibitor cocktail (Sigma) and mixed 
thoroughly and the mixture was incubated for ~1 h.  The lysate was centrifuged at 
16,000 g for two minutes at 4°C and the supernatant was used to perform Western blot.  
 
Harvest of Murine Organs  
Mice were sacrificed using constant-flow CO2 followed by cervical dislocation.  
Internal organs were removed quickly, placed directly into microcentrifuge tubes, and 
were then immersed in liquid nitrogen (for Western blot). Alternatively, the organs were 
placed into cassettes, which were immersed in 10% formalin for 24-48 h followed by 
immersion in 70% ethanol (for immunohistochemistry).  Organs were embedded in 
 22 
paraffin, sectioned, and placed on glass slides.  Organ protein lysate was made by 
cryopulverizing the tissue then immersing the powder in chilled lysis buffer containing 
25 mL/mL protease inhibitor cocktail (Sigma).  The lysate was centrifuged at 16,000 g 
for two minutes at 4°C and the supernatant was used to perform Western blot. 
 
Western Blotting Analysis  
Protein samples were loaded in equal amount in each well of a 12.5% 
polyacrylamide gel and electrophoresed until the protein ladder was fully resolved.  
Proteins were then transferred to nitrocellulose membrane (Biorad), which was blocked 
using 4% milk in TBST (Tris-buffered saline with Tween).  Primary antibodies were 
diluted in 4% milk/TBST and were incubated on the membrane at 4°C overnight, then 
washed three times with TBST. Appropriate horseradish peroxidase-conjugated 
secondary antibodies were added at a 1:2000 dilution using 4% milk/TBST as a diluent 
and incubated for one hour at room temperature.  The membrane was washed three times 
with TBST and luminescence was produced using Western lightning ECL plus detection 
reagent (Perkins Elmer).   
 
Immunohistochemistry (IHC) 
Tissues were embedded in paraffin blocks, and 4-µm sections were cut.  Slides 
were deparaffinized in xylene or a xylene substitute (CitraSolv; LLC, Danbury, CT) for 
2 – 5 minutes. Tissues were hydrated in a series of alcohols and water before undergoing 
antigen retrieval by microwaving in 10-mM citrate buffer. After antigen retrieval, 
endogenous peroxidase activity was quenched with hydrogen peroxide (3% for 10 
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minutes), and sections were blocked with 10% normal goat serum in phosphate-buffered 
saline (PBS) for 30 minutes.  Primary antibodies were applied for times ranging from 30 
minutes at room temperature to overnight at 4°C.  Slides were washed twice for 5 
minutes each in PBS before application of the secondary antibody. For most antibodies, 
slides were incubated with the secondary antibodies for 30 minutes then washed several 
times with PBS. Staining was developed by incubating sections with diaminobenzidine 
and tissue sections were then counterstained with hematoxylin. 
 To identify proliferating cells, we used an anti-Ki67 antibody; to assess 
apoptosis, an anti-activated caspase-3 antibody was used; for sebocyte differentiation, an 
anti-PPAR gamma antibody was employed.   As an alternative method of apoptosis 
detection, the Frag-EL DNA fragmentation kit from Calbiochem was used as per 
manufacturer’s instructions.   All counts were made on multiple sections per animal 
analyzed and means were compared using Student’s t-test. 
 
Hair Follicle Isolation and Flow Cytometry Analysis  
Mice were shaved dorsally two days prior to sacrifice. Just before skin collection, 
Nair was applied to remove remaining stubble. Mice were sacrificed using constant-flow 
CO2 followed by cervical dislocation and then the dorsal skin was removed.  Fat was 
removed from the underside of the skin by thorough scraping with a curved-blade razor, 
and the skin was floated dermis-side-down on 5% (w/v) dispase in DMEM overnight at 
4°C. The following morning, epidermis was scraped free from the dermis, and the latter 
was placed in a dish containing 1% collagenase in DMEM and incubated for ~2 h at 
37°C, or until dermal disintegration was evident.  Dermal remnants were then 
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mechanically dispersed by pipetting and centrifuged for 5 minutes. Microscopic 
inspection revealed intact hair follicles at this stage. 5 mL of 0.25% Trypsin-EDTA was 
added to the hair follicle preparations for 10-15 minutes until a single-cell suspension 
was obtained. These cells were then centrifuged at 1,000 rpm for 5 minutes, resuspended 
in 100 mL of PBS, and incubated with appropriate fluorophore-conjugated antibodies. 
Flow cytometry was performed on a BDAria cytometer and all flow cytometry data was 
analyzed using the FlowJo software program.   Population sizes were compared using 
Student’s t-test. 
 
Epidermal Keratinocyte Isolation and Flow Cytometry Analysis 
Keratinocytes were isolated from telogen dorsal back skin using thermolysin as 
described in Jensen et al (48). Briefly, the back skin strips were rinsed in 10% Betadine, 
then PBS, 70% ethanol, and finally again in PBS. The dermal side was thoroughly 
scraped to remove excess fat, and then the tissue was floated in 0.25 mg/ml Thermolysin 
(Sigma) in calcium-free FAD medium for ~1 h at 37°C. The epidermis was then scraped 
from the dermis, minced with dissecting scissors, and dispersed by gentle pipetting. 
Keratinocytes were further liberated by stirring the epidermal fragments using a 
magnetic stir bar.  Thermolysin was inactivated by adding media containing FBS, and 
the cells were washed with PBS, then pelleted and resuspended in 100 mL PBS for 
labeling with antibodies to CD34, integrin a6, Lrig1, or other molecules.   Flow 
cytometry data was analyzed using the FlowJo software, and cell counts were compared 
using Student’s t-test. 
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Two-Stage Carcinogenesis Experiments 
The dorsal skin of 6-8 week old mice in telogen was shaved two days prior to 
application of  25 ug 7,12-Dimethylbenz(a)anthracene (DMBA) in 200-ml acetone. Two 
weeks later, and for the 24-week duration of the study, dorsal skin was treated with 12.5 
mg 12-O-Tetradecanoylphorbol 13-acetate (TPA) in 200-ml acetone. Papillomas were 
counted weekly, and carcinomas were evaluated visually and confirmed histologically. 
Mice were sacrificed prior to the study’s completion if the combined tumor burden was 
excessive, if morbidity was noted, or if a single tumor exceeded acceptable size limits as 
prescribed by IACUC guidelines. Both female and male FVBs were used in this study, 
but were never housed together. Moreover, males were housed in small numbers in order 
to minimize aggressive behavior (none was noted), which could confound tumor data. At 
the study’s conclusion, tumors were harvested, counted, weighed, photographed, and 
histologically analyzed.  Tumor multiplicities were compared using the Mann-Whitney 
non-parametric rank sum test, while comparisons between tumor incidence were made 
using the Χ2 test.  Tumor masses were compared using Student’s t-test. 
 
Quantitative RT-PCR Analysis  
RNA was extracted using the RNeasy mini kit (Qiagen) with on-column DNase 
treatment to eradicate contaminating genomic DNA or total RNA was extracted using 
the miRVana PARIS kit (Ambion), and sample quality was verified using the Agilent 
Bioanalyzer.  Reverse transcription was carried out using the SuperScript III First-Strand 
Synthesis System (Invitrogen).  Real-time primers were designed using NCBI’s Primer 
Blast online software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and genes to be 
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analyzed were chosen by culling the literature for ChIP studies in which Nanog binding 
was assayed.  Genes to which Nanog bound near the promoter region in both mouse and 
human systems were given preference as likely targets of human Nanog protein binding 
to regions of the mouse genome. 
 
In Vivo Wound Healing Experiments 
Epidermal abrasion experiments were performed by shaving mice 2 days prior to 
wounding.  Hair stubble was removed by application of Nair just prior to epidermal 
abrasion. Mice were anesthetized by inhalation of isofluorane. A felt cylinder was 
attached to an electric handheld rotary tool, and wounds were made superficially such 
that the dermis was just visible. Removal of epidermis and integrity of hair follicles were 
both confirmed histologically on random samples. 
 
In Vitro Wound healing (scrape) assays 
Newborn keratinocyte preparations were made by washing P1-P3 pups 
sequentially in Betadine, alcohol, and water, then sacrificing them using hypothermia. 
Sacrificed pups were skinned and the tissue floated on 0.25% trypsin without EDTA 
overnight at 4 degrees C, following which time the epidermis was gently scraped away 
from the dermis, then minced with dissecting scissors. Additional keratinocytes were 
dislodged from the epidermal fragments by placing the minced epidermis in a medium-
containing dish with a magnetic stir bar and stirring for ~10 min.  Keratinocytes were 
isolated by filtration through a 70-mM cell strainer or by centrifugation in a Percoll 
gradient.  
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The migratory properties of keratinocytes were analyzed using a scrape/wound 
protocol.  Briefly, freshly prepared keratinocytes were plated on collagen-coated dishes 
in a high-calcium Waymouth’s-based (or KBM-Gold) medium and allowed to attach for 
4 h. Then the medium was changed to calcium-free KBM Gold supplemented with 
.05mM  calcium carbonate. Cells were allowed to reach confluence and then a pipet tip 
was used to displace a line of cells along the dish’s diameter. Measurements were made 
0 and 12 h post-scrape/wound, and images were collected at these time points also.  The 
number of cells that entered the scrape area were counted in each of multiple 40x fields, 
and the means of the transgenic and wild-type groups were compared using Student’s t-
test. 
 
Label-Retaining Cell Experiments 
Mouse pups were injected intraperitoneally with bromodeoxyuridine (BrdU) 
twice daily from postnatal day 10 (P10) through postnatal day 12 (P12).  Following a 
chase period of eight weeks, the mice were sacrificed and skin was formalin-fixed and 
paraffin-embedded for histological analysis and anti-BrdU immunohistochemistry. 
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Chapter 3- Generation and Characterization of K14. Nanog Transgenic Mice 
This project began with the intent of answering a simple question, “Does Nanog 
play a role in tumor development?”   Our studies using various loss-of-function 
techniques in prostate cancer cell lines suggested that Nanog was a mediator of tumor 
development. To address these questions in a gain-of-function setting, we first utilized 
the bovine keratin 5 (BK5) promoter to generate a construct bearing HPCa5T Nanog 
(NanogP8) cDNA, which was cloned from a primary prostate tumor.  Implantation of 
microinjected embryos bearing this DNA into pseudopregnant females yielded no 
transgenic founders over the course of over six months and multiple rounds of injection 
(Table 3-1).  Although the keratin 5 promoter should not be active until ~E9.5, 
circumstantial evidence suggested that expression of Nanog from this time point on was 
sufficient to cause embryonic lethality in transgenic animals.   
We then decided to utilize the human keratin 14 (K14) promoter, which is 
expressed in the same cell compartment as the BK5 promoter, but is anecdotally known 
to exhibit relatively reduced expression of the gene of interest.  We reasoned that 
perhaps we would be able to obtain transgenic founders in the absence of dramatic 
overexpression of Nanog protein.  Indeed, after cloning HPCa5T-Nanog cDNA 
downstream of the K14 promoter (Figure 3-1A), we were successful in obtaining a 
limited number of founders, four in all, over several months of embryo microinjection 
and implantation of the embryos into pseudopregnant female mice.  Of these potential  
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Table 3-1 
 
Table 3-1 Summary of BK5.Nanog injections 
In total, 902 embryos were injected with the BK5.Nanog construct over a course of four 
months (additional injections were not catalogued but were performed for two additional 
months),  of which 682 embryos survived (and 629 were transferred to pseudopregnant 
moms). 59 pups were live-born, none of which screened positive for the transgene.  
Additionally, 26 embryos and 34 “aborts” were harvested, but again no transgenics were 
produced. 
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founders, one did not transmit the transgene through the germline, while one mouse that 
bore a wrinkled skin phenotype died two weeks postnatally.  The remaining two 
founders passed the transgene successfully to subsequent generations and were viable.  
Line 1 is marked by relatively high Nanog expression as assessed by Western blot, while 
Line 3 bears moderate transgene expression (Figure 3-2A).   Characterization of the lines 
generated then ensued. 
 
Dose-dependent phenotypes in K14.Nanog mice 
Phenotypically, there is a strong correlation between Nanog expression level and 
severity of the observed phenotype.  At the lower levels of Nanog output observed in 
Line 3, there is no loss of viability and the mice appear grossly normal until about four 
months of age, at which time they begin to develop cataracts that become bilateral by the 
time the mouse is six months old.  As an aside, Line 3 mice that do not develop cataracts 
seem to express the transgene more weakly than do those Line 3 mice that possess a lens 
phenotype (Figure 3-2A).  Thus, it is possible that our colony at some point developed a 
sub-line such that not all Line 3 mice have a propensity to develop cataracts.   
Line 1 mice are characterized by perinatal lethality and possible embryonic 
lethality, with an average litter size of six mice per litter (Figure 3-1C; as compared to 
the standard of ~10 mice per litter when crossing wild-type FVBs) when hemizygous 
males were bred to wild-type females (Homozygous transgenic mice were not generated, 
i.e., hemizygous mice were not crossed due to an expected exacerbation of the reduction 
in viability).   This is consistent with our lack of founders when attempting to generate 
transgenic mice using the BK5 promoter, and strongly suggests that overexpression of 
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Nanog at prenatal time points reduces viability.  Line 1 mice are much smaller than their 
wild-type littermates, and this condition persists throughout birth (Figure 3-1D and E).  
Additionally, Line 1 mice present with wrinkled skin at birth, and as they age they 
acquire shaggy hair coats (Figure 3-1F).  They also possess cataracts, and in this way 
phenocopy Line 3 mice.  However, Line 1 mice develop bilateral cataracts by about one 
month of age, and exhibit hypopthalmia, or reduced eye size, as well.  It should be noted 
that this line’s gross phenotypes seem to attenuate by adulthood, though they are still 
quite prominent.  This effect is compounded by the early death of many transgenic mice; 
those mice surviving past a critical window of roughly two weeks of age seem to bear 
less striking phenotypes than those that expire earlier. 
We decided to systematically analyze transgenic mice for histological 
phenotypes that may not be evident to the naked eye, as the keratin 14 promoter is active 
in a variety of tissues including the skin, forestomach, thymus, and tongue.   
 
Phenotypes-skin 
We began by analyzing the skin, as it exhibits the most prominent gross 
phenotype in Line 1 mice.  First, we confirmed proper expression of Nanog according to 
the expected pattern of keratin 14 expression, and indeed Nanog was localized to basal 
cells of the interfollicular epidermis as well as to the outer root sheath (ORS) of the hair 
follicle (Figure 3-1H).  We examined mice at P5, rationalizing that observations made in 
the window prior to extensive perinatal lethality would prove fruitful.  Indeed, 
K14.Nanog mouse skin appears very different than that of wild-type littermates at this 
time.  Whereas wild-type FVB skin shows orderly follicular arrangement, a distinct 
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hypodermis, and regularly interspersed sebaceous glands, K14.Nanog mice present with 
disorganized follicular arrangement, a paucity of sebaceous glands, and the striking 
absence of a hypodermis (Figure 3-1H).   
In order to gain an appreciation for tissue homeostasis at this time point, we 
conducted Ki67 staining to assess proliferation of the IFE and of hair follicles.  Hair 
follicles are in anagen, the proliferative phase of the hair cycle, at P5, and we confirmed 
this in both transgenic and wild-type mice.  We did find that transgenic mice had a 
noticeable increase in proliferation of the basal cells of the IFE relative to wild-type 
mice (Figure 3-1I and J), although this difference seems to abate by 2.5 weeks of age 
(Figure 3-3G).  This finding is augmented by the presence of keratin 6-positive cells in  
both the IFE and the ORS of the hair follicle of transgenic mice, but only in the ORS of 
wild-type mice (Figure 3-1K), as keratin 6 is considered to be a marker of activated or 
proliferating epidermal cells (59) .  As tissue homestasis is a balance between the 
appearance of new cells through proliferation and the loss of existing cells, which may 
occur through cell death or differentiation, we wondered at the fact that there was no 
visible difference in epidermal thickness between Line 1 and wild-type mice.  To 
address this enigma, we performed IHC staining for suprabasal markers of IFE 
differentiation including keratins 1 and 10 (Figure 3-1K).  We found a slight increase in 
K1/K10 in transgenic mice, which coupled with no detectable difference in apoptosis as 
assessed by TUNEL staining suggests that epidermal hyperplasia was not seen as these 
cells were following the normally-prescribed route of differentiation as they ascend. 
However, we did note abnormal differentiation of the sebaceous gland population, one 
of the three primary epidermal lineages.  As mentioned previously, transgenic mice 
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possess significantly fewer sebaceous glands than their wild-type littermates; this is 
evident both in hemotoxylin and eosin sections and in PPAR-gamma IHC images 
(Figure 3-3B and C). 
 
Wound healing defect in K14.Nanog mice 
During the course of our passive assessment for spontaneous tumor development, which 
lasted upwards of 1.5 years, we noticed that adult K14.Nanog Line 1 mice developed 
extensive wounding on the skin covering their ears; this occurred in the absence of 
pugilism with littermates. As it was unknown whether this was behavorial in nature, i.e., 
the mice were inflicting repeated mechanical stress/damage upon themselves, or whether 
these wounds were arising spontaneously as has been reported in some transgenic 
models (60), we conducted formal wound healing experiments by abrading the 
epidermis with a felt wheel and assessing the regrowth of the removed area.  K14.Nanog 
mice exhibited little re-epithelialization of the affected area, whereas wild-type mice 
showed complete re-epithelialization within a week of abrasion (Figure 3-4A).  It 
became apparent that wounds inflicted on the transgenic mice were not healing from 
inside the wound proper, but instead contraction of the bordering epithelium could be 
observed.  Langton and colleagues demonstrated that such auxiliary wound healing 
occurs in the absence of a contribution from the hair follicle (61), which we suspected to 
be the case in our wound healing system.  As an aside, it appeared that transgenic mice 
were more sensitive to the touch following wounding, and the exposed wounds 
themselves bore a gross inflammatory character including redness along the wound  
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Figure 3-1 
 
Figure 3-1 Characterization of K14.Nanog transgenic mice 
HPCa5T-derived Nanog cDNA was cloned into the human keratin 14 vector to create 
the construct depicted in (A); transgenic mice were screened for using PCR as depicted 
in (B).  Line 1 (L1) litters are much smaller than those of Line 3 or wild-type FVBs (C).  
The L1 mice themselves are smaller as well; this condition persists from birth 
throughout adulthood (D and E).  The most obvious adult phenotype is in the skin of L1 
mice, which bear curly whiskers and shaggy hair (F).  Expression of Nanog protein in 
Line 1 mice is, as expected, strongest in the skin and absent in tissues lacking a keratin 
14 cellular compartment (G).  Analysis of the prominent skin phenotype in Line 1 mice 
at P5 (H-K). 
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Figure 3-2 
 
 
Figure 3-2  Nanog protein expression in transgenic mice 
Line 1 mice bear the strongest levels of Nanog expression in the skin as assessed by 
Western blot (A) and (C).  Note that Line 3 mice that harbor cataracts seem to express 
more Nanog protein than transgenic mice that lack a gross phenotype.  Depicted in (B) is 
a systematic analysis of Nanog levels in keratin 14-expressing organs.  Skin, as 
expected, expressed the transgene more robustly than the other tissues.  Wild-type mice 
do not express mouse Nanog protein in any organs analyzed (D). 
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Figure 3-3 
 
 
Figure 3-3  Characterization of Line 1 skin abnormalities 
K14.Nanog mice (Line 1) lack a hypodermis, have disorganized follicular placement, 
and have relatively few sebocytes (A-C); the abnormalities in the skin are manifest 
grossly as shown in (D).  By two weeks of age, the hyperproliferative phenotype has 
abated although transgenic skin is not identical to that of wild-type littermates 
histologically (E-G). 
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Figure 3-4 
 
 
 
Figure 3-4  K14 Nanog mice exhibit a wound-healing defect 
Epidermal abrasions heal more slowly in K14. Nanog mice than in wild-type FVBs (A).  
In addition, the wounds tend to heal from without rather than from within the wound.  
Markers of activated (keratin 6) and proliferating (Ki67) epidermis do not vary between 
the two groups after two days’ time, although the degree of overall healing by one week 
does (B).  Ex vivo keratinocyte scrape assays suggest than keratinocytes derived from 
transgenic mice are less capable of migrating through an artifical wound than are wild-
type FVB-derived keratinocytes (C and D). 
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margins.  This suggests that the abrasions may cause a more pronounced inflammatory 
response in transgenic mice than in wild-type controls.To better understand the observed 
disparate responses to epidermal abrasion, we assessed the short-term activities of the 
affected skin population histologically.  In both wild-type and transgenic mice, the short-
term wound healing proliferative response as assessed by Ki67 was intact (Figure 3-4B).  
Expression of keratin 6, a marker of activated epidermal cell populations that partners 
with keratin 16, was identical 48 hours post-wounding as well (Figure 3-4B).  
Expression of both of these keratins is essential for cells to properly migrate through the 
wound area (62).  H&E staining at 7 days post-wounding clearly shows that wild-type 
wounds are almost fully re-epithelialized, while transgenic dorsal skin shows a 
discontinuous epidermis and scabbing (Figure 3-4B). 
We wondered if transgenic keratinocytes could migrate properly in response to 
wounding, and to address this issue, we employed an ex vivo assay in which 
keratinocytes derived from newborn pups were allowed to reach confluence, after which 
time a scrape was made through the sheet of cells; this is the artifical “wound”.  We 
observed migration of wild-type and transgenic keratinocytes following the “wounding,” 
and found that fewer transgenic keratinocytes were able to enter the wound at 12 hours 
post-scrape than were wild-type cells (Figure 3-4C and D). 
 
Phenotypes-lens 
We then sought to understand the nature of the shared phenotype between Lines 
1 and 3 in the ocular lens.  It should be noted that the lens is not a keratin-14 expressing 
cellular compartment, but several transgenic models utilizing the artificial human keratin 
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14 promoter to drive expression of human papilloma viruses noted cataract formation 
(63, 64); it is likely, therefore, that the human keratin 14 promoter is missing regulatory 
elements such that transgene expression occurs aberrantly in the lens.  In a normal lens, 
epithelial cells migrate posteriorally toward the bow or ribbon region near the equator, 
and as they do so they begin to enucleate and express early differentiation markers such 
as p57 and later markers such as the various crystalline proteins that allow the lens its 
unique optical properties. 
In the K14.Nanog transgenic lens, this pattern is altered, as nucleated cells are 
found posterior to the lens equator, and vacuolated cells are present within the lens as 
well (Figure 3-5B and D).  The presence of bladder-shaped cells in lieu of normal lens 
epithelial cells suggests an altered cell fate, which we confirmed by staining for beta-
crystallin (Figure 3-5E).  The presence of alternate cell types disrupts the normal lens 
architecture such that the lens becomes opaque; it is likely also that cell-cell interactions 
that serve to stabilize the overall lens architecture are abnormal as well, and that this 
may be a contributing factor to the cataract phenotype.  In Line 3 animals this process is 
gradual and occurs over roughly six months in a Nanog dose-dependent fashion, while in 
Line 1 animals cataracts are evident from as early as one month.   
 
Phenotypes-lingual/digestive 
We were interested in the digestive processes of transgenic mice, as they 
appeared to feed poorly at perinatal time points, often possessing small or absent milk 
spots.  The stomachs of wild-type mice were quite full, but oftentimes transgenic mouse 
stomachs were bereft of food, and as such had thickened adluminal epithelial layers 
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(Figure 3-6A).  We then analyzed the tongue for any possible abnormalities.  H&E 
staining shows that transgenic tongue is wrinkled and hyperkeratinized relative to that of 
wild-type littermates (Figure 3-7A).  Microscopic examination revealed a striking lack 
of filiform papillae, the most abundant of the four types of lingual papillae that are found 
on the dorsal surface and in which taste buds are located, in the tongues of P5 and two-
week-old  transgenic mice (Figures 3-6B and 3-7B and C). We also noted a reduction in 
the level of keratin 13, a marker of a differentiated lingual epithelium layer, and a 
disruption of the normal stratified epithelial organization, again suggestive of a series of 
inappropriate differentiation events (Figure 3-7E).   
 
 Phenotypes-thymus 
In cataloguing the developmental abnormalities in various keratin 14-expressing organs, 
we noticed a striking thymus phenotype.  The thymus in K14.Nanog transgenic mice at 
P5 is much smaller than that of wild-type littermates, even when these numbers are 
normalized to account for differences in body mass.  Even more prominent is the lack of 
delineation between the medullary and cortical regions of the thymus; this lies in stark 
contrast to the well-ordered boundaries between the two in wild-type thymii of age-
matched controls (Figure 3-6C-E).  As it is known that the medulla is formed by the 
expansion of progenitor cells to form islets, and that these islets coalesce to form the 
structure we recognize as the medulla proper (65, 66), it is reasonable to speculate that 
the apparent lack of segregation between the cortex and the medulla in transgenic mice 
may in fact reflect an inability of the progenitor cell population to undergo this requisite 
expansion.  
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Figure 3-5 
 
 
Figure 3-5  Shared lens phenotype between Line 1 and 3 transgenic mice 
Cataracts are evident in both Line 1 (by 1 mo) and Line 3 mice (by 4-6 mo) (A).  
Histological analysis of transgenic eyes shows nucleated cells at the posterior region of 
the lens of K14. Nanog mice (B).  Vacuolated cells and bladder cells are evident in tg 
eyes also (B and D).  B-crystallin staining shows reduced expression of this terminal 
differentiation marker in tg eyes (E). 
 
 
 
 
 
 
 
 42 
Figure 3-6 
 
 
Figure 3-6  Characterization of Digestive and Thymic Ancillary Phenotypes at P5 
Transgenic mice often lack a milk spot at early perinatal time points; this finding is 
confirmed by the absence of food in the stomach of tg mice, which in part leads to a 
hyperkeratinization phenotype in the epithelium bordering the lumen (A).  Because of 
this finding, we examined the lingual epithelium of wild-type and K14. Nanog mice and 
found an absence of filiform papillae (B) that is not rescued by two weeks of age.  An 
unrelated phenotype is found in the thymus, which in transgenic mice is 
disproportionately smaller than in wild-type mice and bears a lack of distinction between 
cortical and medullary regions (C,D,E). 
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Figure 3-7 
 
 
 
Figure 3-7  Abnormal differentiation in SSE of K14. Nanog tongue 
K14.Nanog tongues appear grossly wrinkle and hyperkeratinized relative to those of 
wild-type littermates (A).  Incredibly, they also lack to a large extent the filiform 
papillae, differentiated taste bud structures derive from the stratified squamous 
epithelium (B and C), but retain fungiform papillae (F).  Regions of hyperproliferation 
corresponding to Nanog (+) cells can be observed, and staining for the differentiation 
marker keratin 13 staining presents abnormally as compared to wild-type littermates (E). 
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Chapter 4- Testing Nanog’s Effect on Tumor Development 
Lack of tumor development in K14.Nanog mice 
The thought that germinated this project is that Nanog plays a role in 
tumorigenesis, but after over a year-and-a-half of passive observation, we observed no 
gross tumor formation that was attributable to Nanog expression in the keratin 14 
cellular compartment.  This suggests that Nanog expression in keratin 14-expressing  
epithelia alone is not sufficient to drive tumor formation.  We therefore employed 
methods known to produce tumors in hopes that we would see a perturbation of these 
tumor phenotypes in K14.Nanog animals.   
First, we crossed our K14.Nanog mice with K5.Myc mice in which c-Myc was 
robustly expressed in the keratin 5 cellular compartment.  These mice are known to 
develop spontaneous tumors in the skin and mouth (67), and as such provide a platform 
for us to study the role of Nanog in a setting known to foster tumor development, one in 
which a known oncogene is co-expressed.  We crossed both of our existing lines of 
K14.Nanog mice with K5.Myc mice, but were surprised to find that we could not 
recover double transgenic mice (Table 4-1); shortly thereafter we abandoned these 
crosses as our data suggests that expression of both of these molecules prenatally may 
result in embryonic lethality. 
As an alternative to breeding schemes that would favor tumor development, we 
rationalized that we could observe Nanog’s impact on several well-defined parameters of 
tumor development in a two-stage skin carcinogenesis model.  In this model, initiation 
and promotion are separate entities that can be studied apart from one another. 
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Table 4-1 
K14.Nanog x K5.Myc 
litter Date of birth Number of 
pups 
Line Double-
positive 
pups 
expected 
Double-
positive 
pups 
obtained 
1 9/25/08 6 1 1.5 0 
2 9/29/08 3 3 .75 0 
3 10/7/08 6 3 1.5 0 
4 10/27/08 3 3 .75 0 
5 10/30/08 4 1 1 0 
6 11/26/08 4 3 1 0 
7 12/30/08 6 1 1.5 0 
8 1/6/09 4 3 1 0 
9 1/12/09 10 3 2.5 0 
 
Table 4-1 K14.Nanog/K5.Myc breedings failed to yield double-transgenic pups 
K14.Nanog mice were bred to K5.Myc mice for a period of four months with the 
expectation that adult mice bearing both transgenes would develop tumors at a higher 
rate and with a shorter latency than K5.Myc mice.  However, double transgenic mice 
were not obtained, even though a dozen mice would be expected to be liveborn were 
these breedings proceeding according to Mendelian ratios. 
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We began this protocol with a two-fold working hypothesis:  Either 1) Nanog 
expression may expand the stem/progenitor compartment (as evident in the 
aforementioned Oct4-inducible transgenic model) and therefore increase the number of 
potential carcinogen targets, with the outcome being a higher tumor burden or 2)  Nanog 
may operate more as a classical oncogene, increasing the rate of cellular proliferation (as 
we observed in our P5 skin analyses) and therefore shortening tumor latency.  We were 
therefore puzzled when it became apparent that Line 1 K14.Nanog mice were 
developing fewer tumors than their wild-type and Line 3 counterparts (Figure 4-1B and 
C), and that these tumors were appearing later (at 10 weeks rather than ~8 weeks) as 
well.  Even more surprising was the nature of the tumors themselves:  Whereas 
papillomas arising in wild-type mice were fairly robust at about 40mg/tumor and 
appeared partially vascularized, tumors arising in Line 1 mice were almost one-third the 
size and seemed dessicated (Figure 4-1E and H).  Unsurprisingly, Line 1 tumors did not, 
over the course of the 24-week TPA treatment, become endophytic and progress to 
SCCs, whereas wild-type and Line 3 papillomas did so at a predictable and nearly 
identical rate (Figure 4-1D and F).   
We explored a number of potential causes for these dramatic differences, first 
dissecting the carcinogenesis protocol into its constituent steps in order to determine 
where potential discrepancies may lie.  First, we examined the consequences of DMBA 
application by assessing apoptosis 48 hours after administration of the initiating agent.  
We conducted TUNEL staining to address this issue and found no discernible difference 
between wild-type and transgenic mice. As a further control, we tested Protein Kinase C 
levels in both wild-type and transgenic animals, as PKC activation underlies the bulk of 
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the proliferative response to TPA; we found no noticeable difference between the two 
groups. We then examined the promotion step of the two-stage protocol; specifically, we 
wanted to see if transgenic and wild-type epidermis proliferated in a similar fashion 
when treated with repeated (every other day for two weeks) doses of TPA.  Proliferation, 
as assessed by Ki67 staining, was similar, and both groups exhibited the expected 
epidermal thickening and hyperplasia in response to the two-week TPA regimen (Figure 
4-2A and B). We therefore concluded that a short-term response to neither the initiating 
nor promoting agent was impeding papilloma development. 
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Figure 4-1 
 
 
Figure 4-1  Two-stage skin carcinogenesis 
Mice were initiated with 25ug of DMBA and, after two weeks’ time, lesions were 
promoted with twice-weekly applications of TPA for a period of 24 weeks (A).  Line 1 
transgenic mice did not uniformly develop tumors, though Line 3 and wt mice did (B).  
In addition Line 1 mice displayed a much lower tumor burden than the other groups (C, 
D).  The papillomas that did arise in Line 1 mice were runted and did not convert to 
carcinomas (F).  Histological characterization of tumors arising from all three groups 
(G,H). 
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Figure 4-2 
 
 
Figure 4-2  Hyperplastic response to TPA treatment 
Both wild-type and transgenic mice show increased Ki67 staining after two weeks of 
treatment with the tumor promoter TPA (A).  This is accompanied by a pronounced 
hyperplasia in the IFE of FVB and K14.Nanog mice (B), suggesting a similar 
proliferative response to TPA between the two groups. 
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Chapter 5- Analysis of Skin Stem Cell Populations and Epidermal Gene Expression  
Assessment of skin stem cell populations 
We reasoned that the inhibition of skin tumor development seen in K14.Nanog 
mice may be linked to the failure to repair epidermal wounds.  Both processes require 
the presence and participation of resident stem cell populations (54, 55, 68, 69), so we  
isolated hair follicle keratinocytes and analyzed their cell surface marker profiles to look 
for intact stem cell pools (depicted in Figure 1-2).  We first examined the classical 
CD34+, alpha6 integrin+ stem cell pool, as it is widely regarded as the most crucial and 
primitive of the resident skin stem cell populations.  We found that K14.Nanog skin 
harbored fewer bulge stem cells than age-matched wild-type FVB mice, although the 
cause of this is not immediately apparent (Figure 5-1).  Strikingly, however, we noted 
the apparent diminution of a CD34lowalpha6 integrinintermediate  population in transgenic 
animals.  This population most likely lies above the region of CD34 positivity, and 
therefore resides closer to the epidermis.  This finding, along with our observations in P5 
skin that the IFE is hyperproliferative while sebaceous glands are scarce, suggested to us 
a potential loss of Lrig1+ stem cells.  We therefore isolated epidermal keratinocytes 
using thermolysin instead of trypsin to avoid cleavage of the relevant epitope, and 
discovered that the Lrig1+ population was diminished in transgenic mice (Figure 5-1).  
Since the IFE has a resident stem cell pool of slow-cycling cells, we used the label-
retaining method to identify IFE LRCs by pulsing wild-type and transgenic mice with 
BrdU and chasing for 6 weeks.  Transgenic IFE contained only one-half the number of  
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Figure 5-1  
 
 
Figure 5-1  Diminution of hair follicle stem cell pools 
Keratinocytes were isolated from hair follicles (for CD34, CD49f analysis) and from 
epidermis (for Lrig1 analysis) of two month old wild-type and transgenic animals.  
Wild-type hair follicles seem to possess a CD34lowCD49fintermediate population that is 
lacking in transgenic mice (arrow-wt, hollow circle-tg).   
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label-retaining cells as wild-type epidermis, although their rates of proliferation seemed 
to be roughly equivalent.   
Although we have observed apparent migration impediments and a diminution of 
the resident stem cell pools in the skin of K14. Nanog mice, we did not have an 
explanation at the level of molecular resolution.  We therefore asked, “Which genes 
might Nanog be affecting to bring about the observed phenotypes?”  To answer this 
question, we combed through published studies (14, 70-73) in which Nanog binding to 
gene promoter regions was assayed.  Because our transgenic model involves expression 
of human Nanog in a murine system, we selected those genes whose promoters were 
bound by Nanog in both mouse and human studies.  These conserved targets, we 
reasoned, may be preserved in our artificial system.  We chose 23 genes that fit our 
criteria and designed primers (which spanned introns when possible) for SYBR-green-
based qPCR analysis (Table 5-1; only specific and amplified targets presented).   We 
then extracted total RNA from cryopulverized mouse epidermis of each transgenic and 
wild-type mice and carried out real-time PCR (results displayed in Figure 5-2). 
As is often the case in Science, much of our resulting data was inconclusive, with 
no clear distinction between transgenic and wild-type expression levels.  In some cases, 
no amplified product was observed, suggesting a lack of expression of that particular 
gene in mouse skin.  This group includes Sox2, a finding that is unsurprising given that 
it is chiefly found in the pluripotent embryo. There were, however, a number of targets 
whose altered expression may explain in part the skin phenotypes we observe; the most 
prominent and exciting of this group is the mouse homolog of c-Jun, the subunit of the 
AP-1 transcription factor.  This protein is widely recognized as a proto-oncogene and 
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has prominent roles in skin proliferation, wound healing, and inflammation.  We 
performed IHC staining for c-Jun and found that c-Jun seems to be expressed more 
weakly in transgenic animals.  Additionally, Nanog and c-Jun expression is mostly 
exclusive, that is, they do not overlap to any substantial degree (Figure 5-3).  One highly 
relevant study demonstrated that a transactivation mutant of c-Jun, one that effectively 
reduced the concentration of Ap-1 able to function transcriptionally, was able to impede 
papilloma development in a two-stage protocol (DMBA/TPA) but was unable to block 
TPA-induced proliferation (74).  This is essentially the phenotype we see when we 
subject our K14.Nanog mice to a two-stage carcinogenesis protocol.   
I am unsure if this diminution of c-Jun levels is direct or indirect, however.  
Although large-scale ChIP-seq studies have demonstrated that the c-Jun promoter may 
be a target for Nanog binding, there exists the very small possibility that this promoter is 
among those inevitable false-positive results inherent in such large-scale genome 
analyses.  Additionally, the binding may be authentic yet there may be no relevant 
repressive activity directly exerted by Nanog.  It is also possible that Nanog binding to 
the promoter prevents other transcription factors from occupying certain regions 
upstream of the transcription start site, and thus a direct repressive effect may exist.  This 
can be experimentally tested by conducting an immunoprecipitation (IP) experiment 
using epidermal lysate.  Immunoprecipitating Nanog will probably result in the pull-
down of associated proteins, and the authenticity of these interactions can be confirmed 
by performing a reciprocal IP.  A final possibility, owing in no small measure to the 
complexity of transcription factor gene expression networks, may be that lowered c-Jun 
levels are simply an indirect consequence of Nanog expression in the skin, a locale from 
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which it is normally absent, although the fact that Nanog and Jun seem not to colocalize, 
i.e., Jun seems absent or low in Nanog-positive cells argues against this. 
Another potentially exciting finding is that the lower levels of Bmp5 in the 
epidermis of transgenic mice may explain in part our apparent stem cell depletion.  A 
study published in 2011 from the Morris lab showed that Bmp5 levels are strongly 
correlated with and directly proportional to ex vivo colony formation and in vivo label-
retaining cell number (75).   Additionally, we have identified fibroblast growth factor 
receptor 2 (Fgfr2) and Jmjd1a (a well-known lysine demethylase) as downregulated 
genes in K14.Nanog epidermis, but have yet to follow up on the potential significance of 
these finding.  It is likely, of course, that our screen has failed to identify some genes 
that are causally related to the skin phenotypes we have observed, and that ascribing one 
gene to each observed phenotype is a dramatic oversimplification. 
A close inspection of our qPCR data shows that target genes seem to be, on the 
whole, repressed rather than elevated in transgenic mice (refer again to Figure 5-2).  This 
may reflect a direct repressive event, such as the reported binding of Nanog to Smad1, 
which blocks bone morphogenic protein (BMP) signaling (76), or an indirect repressive 
event, such as Nanog occupation of promoters impeding normal binding of endogenous 
transcription factors. 
 
 
 
 
 
 
 
 55 
Table 5-1 Primers used in epidermal gene expression studies 
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Figure 5-2 
 
Figure 5-2  Epidermal gene expression panel 
Genes chosen represent those whose promoters have been shown to be bound by Nanog 
in human and mouse systems.  Many of the genes analyzed are not significantly different 
between the two groups, suggesting that Nanog may not be sufficient to regulate these 
genes in the skin.  However, the expression of Jun, BMP5,FGFR2, and Jmjd1a are all 
drastically diminished (and statistically significant; p<.05) in transgenic skin.    
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Figure 5-3 
 
 
Figure 5-3  c-Jun levels are reduced in K14.Nanog epidermis 
We assessed c-Jun protein levels by IHC after two weeks of treatment with the tumor 
promoter TPA.  K14.Nanog skin showed lower levels of the proto-oncogene than did 
wild-type FVB skin (compare c to e and g).  In addition, c-Jun expression is mostly 
exclusive with Nanog expression (serial sections f and g), even though Nanog–
expressing cells are found basally and suprabasally in the IFE.  In contrast, wild-type 
skin shows more basal c-Jun expression (denoted by black arrows in c).   
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Chapter 6- Ongoing Projects, Future Directions, and Significance 
Ongoing-Prostate-specific Nanog expression:  A constitutive model 
Because much of our data concerning Nanog expression in cancer was garnered 
in the prostate, we wanted to specifically and robustly express Nanog in that organ.  I 
cloned the HPCa5T-Nanog cDNA into the ARR2Pb vector, which directs expression 
primarily to luminal cells in the dorsal, ventral, and lateral prostate lobes in the mouse 
(44).  We were able to easily generate founders, and characterization of F1 offspring 
revealed robust Nanog expression in the expected locales.  Whole-mount H&E sections 
failed to reveal any hyperplastic or PIN-like lesions in mice ranging from two to six 
months old (Figure 6-1), but sometimes mild luminal crowding may be seen. Although 
this does not formally exclude Nanog expression from being sufficient to confer 
oncogenic phenotypes in the prostate, that possibility is reinforced by our findings in the 
K14.Nanog model.  Additional studies to create a more favorable setting for 
tumorigenesis, e.g., by increasing the activity of resident stem cells through androgen-
dependent regression-reconstitution cycles will be undertaken in the future to address 
this question.  Additionally, because the probasin composite promoter is the most 
common means of targeting gene expression specifically to the prostate, the possibility 
exists to cross this mouse model with a transgenic mouse line bearing essentially any 
oncogene of our choosing.  There also exists the possibility of crossing the K14.Nanog 
mouse model with the probasin-Nanog mouse to target Nanog to both the luminal and 
basal cell compartments simultaneously. 
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Summary/Significance 
The significance of this work is multifaceted:  First, we have generated two 
constitutive models that allow for the study of Nanog in a number of different tissues; 
similar models exist for many of the other prominent ES cell transcription factors, but 
this is the first Nanog transgenic model that is available to the scientific community.  
This model may be crossed with other models of various diseases, as we have done 
previously, to study a potential role for Nanog in those pathological processes.  
Secondly, we have demonstrated that, at least in keratin 14 cellular compartments and 
possibly in prostate luminal cells, Nanog overexpression is insufficient to cause 
tumorigenesis.  It remains an open question as to whether or not Nanog can function 
oncogenically in the context of other malignancy-predisposing events.  It seems 
reasonable to suspect, based on our skin tumorigenesis data, that Nanog expression at 
high levels may instead confer a tumor suppressive phenotype in certain tissues.  Thus, 
like many proposed oncogenic molecules, Nanog expression may have varying effects 
on tumor growth, progression, and the like depending on the relevant cellular context.  
This dose-dependent phenotype is also very reminiscent of the role Nanog plays in ES 
cells. The observed phenotypes are probably highly dependent on the transcriptional 
program, or portion thereof, that Nanog can enact in somatic cells in the absence of some 
if not most of the cofactors and other transcription factors with which it is normally 
found in complexes in ES cells.  In fibroblasts and other cells in which Nanog has been 
used to induce pluripotency, neither it nor any of the other transcription factors alone can 
reprogram somatic cells to a pluripotent state, and in ES cells low transcription factor 
occupancy correlates with absence of gene expression. 
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Future studies 
 There remain a number of experiments yet to be conducted involving the 
K14.Nanog mouse model.  The most pressing of these involves functional validation of 
the stem cell depletion phenomenon seen in these mice.  To address this issue, ex vivo 
holoclone assays will be used as a readout of stem/progenitor cell number.  If a reduction 
in holoclone-forming cells is observed, then we can conclude with some confidence that 
stem cell populations are diminished in K14.Nanog mice.  Further, we will test whether 
addition of exogenous Bmp5 can rescue this phenotype, as has been shown by the 
Morris lab.  If this is not the case, i.e., there is no reduction in colony-forming cells then 
the altered expression of stem cell markers that we observe in our transgenic mice may 
be seen instead simply as an abnormal display of cell surface markers.    
 Confirmation of our qPCR data is important also to solidify the conclusions we 
have drawn.  To this end, Western blot of epidermal lysates for c-Jun, Bmp5, and 
perhaps Fgfr2 or Jmjd1a will be effected.  In the case of Bmp5, this may not be feasible 
as it is a secreted protein, so IHC may be used as an alternative, or, failing this, the 
holoclone rescue experiments may suffice to validate our findings. 
Future work beyond the scope of this mouse model will most likely entail 
moving away from a constitutive model and instead using an inducible model of Nanog 
expression, as any potential confounding effects owing to developmental abnormalities 
will be removed by selectively expressing Nanog during adulthood.  Recently, we have 
overcome technical hurdles that precluded gain-of-function studies in vitro, so in order 
to more accurately study Nanog in prostate cancer, the original setting in which we 
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identified expression of this molecule, we will make prostate cancer cell lines the 
emphasis of future work. 
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Figure 6-1 
 
 
Figure 6-1  Genesis and characterization of ARR2Pb- (Flag) Nanog Mice 
The construct used for pronuclear injections is depicted in (A).  In brief, tumor-derived 
Nanog cDNA bearing an N-terminal Flag epitope is under the control of the androgen-
responsive probasin promoter.  (B-E)  No significant differences exist in terms of gross 
morphology or in histological characterization of the glandular structures in the dorsal 
prostate (DP), although mild crowding of the tg lumen may be observed. 
Part 2- Nanog and miR-128a 
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II.  Nanog and miR-128a 
Chapter 7- Introduction and Background 
Introduction 
 During our intensive work concerning Nanog’s role as a potential oncogene, the 
protein remained elusive in many cell types (ex. PC3), yet our results clearly show that 
reducing Nanog RNA yields a tumor-suppressive effect in these same cancer cells.  This 
raised the possibility that the Nanog mRNA was a biologically important species, and 
further work suggested that it may be a molecular sink for one or more tumor-
suppressive microRNA (miRNA) species.   MicroRNAs are endogenous regulators of 
gene expression; these small nucleotides are 19-22 nucleotides in their mature form and 
act primarily to attenuate levels of their target mRNAs.  MiRNA levels are often 
perturbed in cancer; tumor-suppressive microRNAs are lost or reduced and oncogenic 
miRNAs are amplified or otherwise increased.  In this way, microRNAs behave 
according to classic cancer gene dogma.  However, whereas many oncogenes and tumor 
suppressor loci have been identified, microRNAs are still something of an enigma; even 
though potential tumor suppressor microRNAs and oncogenic microRNAs have been 
identified, it is often unclear which mRNA targets are at the nexus of a given 
microRNA’s biological effect.   
   We have identified a direct relationship between microRNA 128a, a tumor 
suppressive microRNA with known targets that are important in prostate cancer 
development, and the Nanog mRNA through its 3’ untranslated region.  We are now 
conducting experiments to test the biological significance of this finding. 
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Background 
MicroRNAs (miRNAs) are small endogenous RNA species roughly 19-22 
nucleotides in length that are capable of disproportionately large feats of gene expression 
modulation.  Mature microRNAs act by binding to partially or fully complementary 
binding sites in the 3’ untranslated region (UTR) of target messenger RNA (mRNA) 
species; this binding of one or more microRNAs to their respective targets destabilizes 
the message and leaves it susceptible to degradation.  It has been speculated, and in some 
cases demonstrated, that a single microRNA species may have hundreds of potential 
targets.  Conversely, each messenger RNA species may be regulated by multiple 
microRNAs, depending upon the length of the 3’UTR and the number of binding sites 
contained therein.  Interestingly, it has also been reported that some microRNAs may act 
on the coding region of target genes, e.g., (77), although the parameters that define such 
interactions are less understood.   
MicroRNAs were discovered quite by happenstance, and this discovery 
revolutionized our way of thinking about gene expression.  These small RNA species 
represent a way to fine-tune messenger RNA levels, in some cases allowing for rapid 
gene expression by suppressing the mRNA until removal of the relevant microRNA.  
Initially, it was thought that imperfect complementarity between the microRNA seed 
sequence and the 3’UTR of an mRNA resulted in transcript degradation, whereas perfect 
complementarity was thought to elicit a mysterious translational repression that defied 
molecular characterization.  A recent study that employed high-resolution ribosome 
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profiling determined that most, if not all, microRNA activity occurs through 
destabilization of the transcript rather than through translational repression (78).    
MicroRNAs are highly conserved and possess a myriad of functions 
including developmental regulation, metabolism, and control of cellular proliferation 
(79). The intervening years since the discovery of microRNAs have taught us a great 
deal about their biogenesis and how this process may go awry in causing or contributing 
to disease.  In normal miRNA genesis, primary transcripts, known as pri-miRNA species 
(which may originate from coding genes or which may be intronic in nature) are cleaved 
by a Drosha-containing complex to yield pre-mRNAs. The stem-loop-bearing pre-
miRNA is exported to the cytoplasm where it is processed by a complex that includes 
Dicer along with Argonaut accessory elements . This yields the mature miRNA species 
that binds in a semi-complementary fashion to a plethora of mRNA targets and effects 
their destabilization, thereby rendering them unavailable for translation, or in rarer cases 
involving extensive base pairing between miR and mRNA, leads to the message’s 
outright destruction through RISC complex-mediated cleavage.  It is well-established 
that large-scale DNA alterations such as deletions, translocations, and the like can 
perturb levels of pri-miRNA during neoplastic transformation, but post-transcriptional 
miRNA regulation has also been postulated as a contributing factor in this process (80).  
A powerful example of this is the relationship between let-7 and the RNA-binding 
protein Lin28.  Let-7 is considered the classical example of a tumor suppressive 
microRNA, as it possesses high affinity for oncogenes such as Ras, Hmga2, and 
Caspase 3 (81-83) and is diminished in lung cancer (84).  Lin 28 acts to sequester let-7 
and other microRNA species, which allows terminal uridyl transferases (TUTs) to 
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associate with the RNA-protein complex and tag the pre-microRNA species for 
degradation by adding multiple uridyl residues to the 3’end of the miRNA (85, 86). 
 
MicroRNAs and non-coding RNA species 
Recently, it has become apparent that pseudogenes may regulate microRNA 
activity.  Pseudogenes are molecular fossils, incomplete or otherwise non-functional, 
i.e., non-protein-coding genes born of the parental locus and inserted back into the 
genome in a different location (usually through a retrotransposition event).  In the rare 
case that such a doppleganger gene retains the ability to encode a functional protein, it is 
instead designated a retrogene.  Genes that are expressed embryonically are more likely 
to possess pseudogenes, as transposons may be active in the relatively accessible 
chromatin configuration present during this window of development.  In fact, Oct-4 has 
upwards of 13 pseudogenes, while Nanog has 10 pseudogenes and one retrogene.  These 
pseudogenes may be of two forms, processed or unprocessed, each reflecting a different 
origin.  Processed pseudogenes are derived from expressed mRNA that undergoes 
retrotransposition and is inserted into the genome, and therefore these species lack 
introns and promoters of their own.  Non-processed pseudogenes arise from duplication 
of the parental gene; over time and in the absence of selective pressure these duplicates 
acquire mutations, deletions, and the like that render them non-functional. 
Because of their similarity to transcripts encoding functional gene products, 
pseudogenes are oftentimes confused for their parental transcripts, and as such 
experimental design (including choice of primers) and interpretation must be undertaken 
carefully.  A report in 2007, issued amidst a flurry of stem cell research, cited numerous 
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other studies as derelict in considering Oct-4 pseudogenes in their work, and concluded 
that significant confusion had been created in the scientific community as a result (87) .   
The molecular resemblance of a pseudogene to a parental gene of origin serves as 
more than an experimental irritant, however.  As psueudogene transcripts “look” like 
bona fide protein-coding gene mRNAs, they may serve as decoys for the various 
mechanisms that regulate mRNA transcripts, including microRNAs.  In instances where 
the transcript has retained relevant 3’UTR or coding region miRNA binding sites, the 
microRNA may bind to the “artificial” transcript instead of the authentic one; in this 
way, miRNA activity is diverted away from a particular gene.  This phenomenon was 
demonstrated convincingly using PTEN and its decoy pseudogene PTENP1 as 
archetypes, as targeting of PTENP1 results in an increase in microRNA-mediated PTEN 
loss (88).  This ability of pseudogenes to sponge or subvert miRNA activity represents 
yet another layer of regulation of microRNAs, as the mature form must navigate a sea of 
potential binding partners in order to exert its influence on a “true” target. 
 
MicroRNA 128a- a candidate tumor suppressor 
Among the class of tumor suppressive microRNAs, miR-128a represents a 
largely uninvestigated miR that may be highly relevant to the development and 
progression of prostate cancer.  It is among a handful of microRNAs that is significantly 
expressed in the neuronal lineage: It is largely absent from neural stem cells (89) but is 
highly expressed in mature, terminally-differentiated neurons (90).  A number of recent 
studies lend credence to the notion of miR-128a as a tumor suppressor in glioma, 
including those that identified Bmi1 and E2F3 (91, 92), two proteins whose 
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overexpression is known to contribute to tumorigenesis, as potential targets.   Evidence 
of mir-128a’s role in suppression of prostate cancer comes in the form of a proteomics-
based study in which miR-128a targets were found to be expressed at higher levels in 
prostate adenocarcinomas than in benign prostatic tissue (93); indeed, metastatic PCa 
showed even higher levels of these proteins than in situ disease, suggesting that miR-
128a is progressively diminished during progression of the disease.  Loss of miR-128a 
was shown to result in increased invasion and migration of prostate cancer cells in vitro.  
Even more promising was the finding that miR-128a levels are consistently lower in 
primary prostate cancer samples than in benign tissue (94).  The great unknown in this 
equation is how miR-128a levels are diminished in prostate cancer.  To date, no 
mechanism of miR-128a loss has been reported, yet all of the usual suspects are 
possible, including but not limited to promoter methylation/chromatin silencing, genetic 
deletion, and the tantalizing possibility that decoy mRNA transcripts are increasingly 
expressed as cells become malignant. 
A promising but unelaborated-upon finding in this work is the close relationship 
between the Polycomb1 complex protein expression signature and that of microRNA 
128a.  This greatly augments the connection between miR-128a and Bmi1 in prostate 
cancer and suggests an inverse relationship between the two.  Bmi1 normally functions 
by associating with RING1B, PH1, and CBX4 in the Polycomb1 complex; this cluster of 
proteins is responsible for reading the H3K27 repressive chromatin mark laid down by 
the Polycomb 2 complex, which is composed of an EZH2 enzyme, as well as EED, 
SUZ12, and RBPA48 accessory proteins.  Bmi1/Polycomb1 complex silencing is 
thought to be dependent on the complex’s ability to add ubiquitin to H2A, which may 
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result in RNA polymerase pausing or cessation of transcription (95).  It is well-
established that Bmi1 is overexpressed in many instances of prostate adenocarcinoma, 
and it has been recently evinced as an important mediator of self-renewal in normal and 
malignant prostatic stem-like cells (96).   
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Chapter 8- Materials and Methods 
Cell culture 
 LNCaP, PC3, and DU145 cells were cultured in RPMI media (Invitrogen) 
supplemented with 8% fetal bovine serum (FBS).  RWPE-1 cells were cultured in KBM-
Gold medium (Lonza) supplemented with additional growth factors.  All cell culture was 
performed in antibiotic-free conditions. 
 
Clonal and clonogenic assays 
Clonal assays were conducted by plating 100 or 200 cells per well of a six-well dish 
following experimental manipulation.  Cells were allowed to attach for 24-48 hours 
before the media was changed.  Colonies were scored and photographed two weeks later. 
Clonogenic assays were performed identically but cells were plated on low-attachment 
tissue culture dishes.  Spheres were counted and photographed two weeks post-plating. 
 
Luciferase assays 
The Nanog 3’ UTR was cloned into the MCS of pMirREPORT (Ambion); a renilla 
luciferase-coding plasmid was used as an internal control.  Cells were seeded 40k per 
well of a 24-well dish and allowed to attach for 24 hours prior to transfection.  Mir-128a 
and a non-targeting control (Ambion) were transfected into target cells at a final 
concentration of 32nM using either Lipofectamine 2000 or RNAiMAX (Invitrogen/Life 
Technologies) reagents per the manufacturer’s protocol.  48 hours after transfection, the 
Dual Luciferase assay kit (Promega) was used to induce chemiluminescence, which was 
detected and measured on a Gen-Probe chemiluminometer. 
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Site-directed mutagenesis 
The 9-mer seed sequence of the miR-128a binding site in the Nanog 3’UTR was mutated 
from 5’ TTCACTGTG to 5’ TTCGAGTTG using the Stratagene QuikChange kit as per 
manufacturer’s instructions. 
 
RNA extraction and quantification of Mir-128a 
Total RNA was extracted from cultured cells using the Mirvana PARIS kit (Ambion).  
Briefly, cells were lysed in a mild buffer and RNAses were inactivated with subsequent 
addition of a GITC-containing buffer.  Acid phenol-chloroform was added, and the 
aqueous phase was harvested following centrifugation.  This was mixed with 1.25x 
volumes of ethanol and applied to a glass-silica column, centrifuged, washed, and eluted 
with nuclease-free water.  RNA integrity was analyzed on the Agilent Bioanalyzer 
nanochip.  MicroRNA was reverse transcribed using the Taqman MicroRNA reverse 
transcription kit, and microRNA levels were determined using the Taqman Small RNA 
assay assay (Applied Biosystems).  Sample measurements were averaged and means 
were compared using the Student’s t test. 
 
Nanog knockdown via siRNA 
Prostate cancer cells were plated and allowed to reach three-fourths confluence prior to 
transfection with siNanog SMARTPOOL siRNA or non-targeting SMARTPOOL 
siRNA (Dharmicon) using RNAiMAX transfection reagent (Invitrogen).   
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Nanog knockdown via lentiviral-mediated short hairpin RNA 
Lentivirus bearing a short-hairpin RNA directed against Nanog or bearing no shRNA 
(empty vector) was generated as previously described (36).   Cells that expressed the 
short hairpin or empty vector were selected by sorting for GFP+ cells using a BDAria 
flow cytometer. 
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Chapter 9- Examining the Nanog/miR-128a axis  
Nanog regulation by mir-128a 
Our previous work showed that diminution of Nanog RNA levels had a drastic impact 
on prostate cancer development (36).  However, our transgenic models of Nanog 
overexpression, both keratin 14- and ARR2Pb-driven, failed to show any neoplastic or 
even pre-neoplastic alterations.  Additionally, the protein has remained elusive- as 
assessed by Western blot, mass spectrometry, immunoprecipitation, etc…- in various 
primary and cultured cancer cells such as PC3, although the prostate cancer cell line 
DU145 numbers among those cell lines where the protein is scant yet present.  A 
compelling study from the Orkin lab demonstrated that the so-called “ES cell gene 
expression signatures” thought to be evident in somatic cancers were in fact largely a 
reflection of the transcriptional program carried out by Myc (97), a well-known 
oncogene and transcription factor that is expressed at high levels in many cancer types. 
We therefore could not exclude the possibility that the biologically-relevant species in a 
cancerous context is the RNA rather than the protein.  With the introduction of a 
“ceRNA” hypothesis by the Pandolfi lab (98), one in which RNA species regulate one 
another by competing for microRNA binding , we wondered if this model may apply to 
our Nanog loss-of-function observations.  Our animal models and subsequent in vitro 
gain-of-function experiments failed to account for a potential role of the Nanog 3’UTR, 
as our cloned Nanog cDNA lacks the 3’UTR that is instrumental in microRNA 
regulation. 
In order for Nanog to fit this paradigm, it should be capable of acting as a 
molecular sink to siphon off potential tumor suppressive microRNAs from their bona 
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fide targets.  We therefore conducted a thorough search of the various microRNA/ miR 
target databases and combined this approach with an exhaustive literature search in order 
to determine if the Nanog 3’UTR contained any binding sites for tumor suppressor 
microRNAs.  Two independent microRNA target prediction algorithms, MicroCosm V5 
and miRanda, indicate a strong binding site for mir-128a in the Nanog 3’UTR (Fig 9-
1A).  In fact, this is the only microRNA binding site in the 3’UTR that is predicted by 
both computational programs. 
In order to test whether or not this predicted binding could occur biologically, I 
utilized the pMIR-REPORT vector into which the Nanog 3’UTR had been cloned 
upstream of the firefly luciferase coding sequence.  Addition of mir-128a, but not non-
targeting microRNA, resulted in greatly diminished luciferase output (Fig 9-1B and C).  
Mutation of the seed sequence entirely abolished miR-128a regulation of Nanog 3’UTR-
dependent firefly luciferase activity.  This suggests that the Nanog 3’UTR is a bona fide  
target of miR-128a.    
To further this point, I wanted to determine if depletion of endogenous Nanog 
mRNA could liberate miR-128a.  I predicted that removing Nanog RNA via siRNA 
knockdown would result in a net increase in the levels of  miR-128a, and I therefore 
transfected PC3 and LNCaP cells with siRNA (directed against Nanog or noncoding) 
and assayed microRNA-128a levels 48 hours later.  I found that miR-128a levels 
consistently increased by about 16-17% in those cells that were robbed of Nanog mRNA 
(Fig 9-2), suggesting that Nanog mRNA is a potent reservoir for miR-128a.  To extend 
this finding to situations in which Nanog is chronically absent, I introduced a GFP-
expressing lentivirus bearing a short hairpin RNA directed against Nanog (or an empty 
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vector) into PC3 cells and sorted for GFP-positive cells.  Cells in which Nanog was 
diminished expressed roughly 40% more miR-128a than cells that were infected with 
only the empty vector. 
 
Mir-128a as a tumor suppressor in PCa 
Next, I opted to test whether miR-128a, which has been reported to inhibit 
growth of glioma cells, can function as a tumor suppressor in prostate cancer cells as 
well.  To this end, I transfected miR-128a or non-targeting microRNA control into 
LNCaP cells and assayed for clonal growth.  After two weeks, only one-third the number 
of cells transfected with mir-128a as compared to those transfected with a non-targeting 
species had established holoclones (Fig 9-3A).   Primary clonogenic assays, which 
measure both a cell’s ability to grow in anchorage-independent conditions and its 
proliferative capacity, revealed no difference between the two groups.  However, 
secondary clonogenic assays, a better representation of the stem cell-like property of 
self-renewal, showed that fewer mir-128a-transfected cells could form spheres than 
could non-coding miRNA-transfected cells (Fig 9-3B and C).   
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Figure 9-1 
 
Figure 9-1 Mir-128a can regulate the Nanog 3’UTR The nucleotide alignment of mir-
128a’s mature form and the relevant predicted binding site in the Nanog 3’UTR suggest 
a strong interaction (A).  Luciferase experiments confirm the strength of the interaction, 
as the presence of this binding site alone is sufficient to confer a 60 percent reduction in 
luciferase output when exogenous miR-128a is added (B); this phenomenon can be 
observed in DU145 cells as well (C).  Mutation of four nucleotides in the seed region 
renders miR-128a unable to act on the Nanog 3’UTR (B); interestingly, firefly luciferase 
activity soars well past the baseline. 
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Figure 9-2 
 
Figure 9-2  Reduction of endogenous Nanog levels leads to an increase in miR-128a 
levels 
I employed two different strategies to determine if loss of one potential target mRNA 
species would result in an increase in mature, “free’ miR-128a.  First, I employed a long-
term, stable knockdown of Nanog by infecting PC3 cells with a lentivirus that expresses 
a short hairpin RNA targeting Nanog.  When compared to an empty vector control, cells 
in which Nanog has been targeted show a 40-percent increase in miR-128a levels.   
The second strategy uses siRNA for short-term analyses:  Cancer cell lines (including 
PC3 and LNCaP) in which Nanog levels have been diminished show an approximate 17 
percent rise in miR-128a 48 hours after transfection with siRNA.  
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Figure 9-3 
 
 
Figure 9-3 Mir-128a impacts PCa cell line clonal and clonogenic growth 
LNCaP cells transfected with miR-128a display one-third of the number of holoclones 
relative to controls after two weeks (A).  Primary clonogenic assays, which measure 
anchorage-independent growth and proliferative potential, showed no difference 
between cells transfected with miR-128a and those transfected with a non-targeting 
artificial microRNA (B).  However, secondary clonogenic assays confirm that sphere-
forming ability is progressively lost when exogenous mir-128a is added (B and C). 
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Nanog mRNA miR-ly as a sponge?  
 It is likely though unproven that a given mRNA message may bind more than 
one microRNA species at a time if the relevant binding sites are unoccupied, and that 
this binding is dynamic and constantly in a state of equilibrium.  If this is the case, then 
it is also likely that the sum total of a particular RNA message’s impact on the 
microRNA pool is determined by the number of miRNA binding sites and the affinity of 
those binding sites for their respective microRNAs.  It is therefore likely that Nanog’s 
3’UTR does not only contribute to tumorigenesis by acting on miR-128a, but may act on 
other species in parallel or even simultaneously.  One promising target is mir-34a, a 
tumor suppressive microRNA that our lab identified as a potent regulator of cancer stem 
cells through CD44.  We conducted preliminary studies into the possible connection 
between mir-34a and Nanog, but although luciferase assays showed regulation of the 
Nanog 3’UTR by mir-34a, the activity was weak and we therefore decided not to pursue 
that avenue of research any further.  However, a recent paper has confirmed this 
regulation in demonstrating that mir-34a impedes reprogramming of somatic cell (99), 
and thus it seems likely that the Nanog 3’UTR may be able to act as a sponge for this 
important tumor suppressor as well.   
Conversely, it is highly probable that Nanog mRNA is not the sole RNA decoy 
for miR-128a (or miR-34a, for that matter).  As this concept is in its nascency, a 
systematic study of pseudogenes and other likely RNA sponges (e.g.  long intergenic 
noncoding or linc RNAs) that are expressed in somatic cancers has not been conducted.  
It is likely also that protein-coding genes may be activated in order to siphon off 
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microRNAs, provided that those genes’ protein products do not impose undue 
proliferative or other competitive constraints on the cancer cell. 
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Chapter 10- Significance and Future Directions 
Future Studies 
I am currently in the process of conducting in vivo xenograft experiments in 
order to verify miR-128a’s potential as a tumor suppressor in prostate cancer.  In 
addition, I will attempt to determine if expressing the Nanog 3’UTR alone can enhance 
tumorigenesis.  As it is believed that Bmi1 is one of the most important targets for mir-
128a in the prostate, and perhaps the most important of its targets during development of 
prostate cancer, I will conduct immunoprecipitation of Argonaut proteins and perform 
real-time PCR in both Nanog-depleted and control samples.  This would be the most 
powerful method of showing that the Nanog transcript is shielding Bmi1 from 
microRNA activity; it would also allow for the effect of other potentially shared 
microRNAs to be observed.   
Additionally, it will be important to test how Nanog mRNA functions as a 
ceRNA in its native setting, that is, in ES or even embryonal carcinoma cells.  In this 
setting, the mRNA is much more abundantly expressed, and the protein is abundant as 
well, so this may well represent an instance of a protein-coding mRNA species acting to 
regulate other mRNA species.  This would not be unsurprising given the complexity 
inherent in establishing and maintaining the pluripotent state in the blastocyst and its in 
vitro derivative.  This system can also be employed in order to test whether miR-128a 
activity can, as expected, decrease the level of the Nanog protein.   
Exciting, large-scale studies aimed at identifying the range of ceRNAs which 
Nanog mRNA may compete with for microRNA binding are beyond the scope of this 
 82 
lab’s expertise, but fully elucidating these competitors will allow for a better 
appreciation of the biological role of Nanog mRNA in the setting of tumorigenesis. 
 
Significance 
It is important to determine in which cancers or even in which individual tumors 
Nanog is expressed solely at the level of RNA, as we cannot rule out oncogenic activity 
of the protein, although the latter seems mostly confined to germ cell tumors.  This may 
be because of the ironclad nature of the silencing that ES-cell/pluripotency genes seem 
to undergo as they transition to somatic cells.  In essence, any latent contribution to 
tumor growth is strictly hypothetical as the parental genes are unable to undergo 
reactivation.  The form of Nanog that we detect in cancer cells originates from the 
NanogP8 locus, which lacks a promoter of its own; expression from this region of the 
genome is therefore very minimal. This may explain why the protein is essentially 
undetectable in many cancer cell types, as the mRNA must overcome a variety of 
obstacles including microRNA-induced instability and exosome activity before ever 
encountering a ribosome.  If further work determines that Nanog mRNA is the important 
biological species in somatic tumors, this will ameliorate cancer research by de-
emphasizing work on the Nanog protein as a potential effector of tumorigenesis and 
instead will highlight the appropriate miRs, including miR-128a, and their respective 
authentic, protein-coding targets.  A final possibility is that in circumstances where the 
protein is evident, the Nanog mRNA and protein each may be oncogenic entities and that 
their combined actions may collaborate to effect tumor development though different 
mechanisms. 
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